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Air pollution is increasingly recognised as an important and modifiable risk 
factor for cardiovascular disease. Exposure is associated with a range of 
adverse cardiovascular events including hospital admissions with angina and 
myocardial infarction, and with cardiovascular death. The main arbiter of 
these adverse health effects appears to be combustion-derived nanoparticles 
that incorporate reactive organic and transition metal components. Through 
the induction of cellular oxidative stress and pro-inflammatory pathways, 
these nanoparticles exert detrimental effects on platelets, vasculature and 
myocardium, and can augment the development and progression of 
atherosclerosis. 
 
Over the last 10 years there has been remarkable progress in the 
development of targeted engineered nanoparticles as contrast agents to 
enhance cellular and molecular imaging. Ultra-small paramagnetic iron oxide 
(USPIO) nanoparticles (<100 nm) produce disruptions in the magnetic field of 
magnetic resonance imaging (MRI) scanners, and a decrease in image 
intensity in areas where the particles accumulate. USPIO particles are 
phagocytosed by cells of the monocyte-macrophage system throughout the 
body including within atheromatous plaques. USPIOs have regulatory 
approval in the United Kingdom for imaging lymph nodes in breast and 
prostate cancer as well as FDA approval for parenteral iron-replacement 
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therapy in chronic kidney disease. There is great interest in developing 
USPIO and other nanoparticle contrast agents for imaging atherosclerosis.  
 
The delivery of engineered nanoparticles (ENPs) directly into the 
bloodstream to provide enhanced imaging of the unstable atheromatous 
plaque may assist in the diagnosis of plaque rupture and may ultimately 
permit targeted delivery of therapies directly to the site of vascular injury. 
However, these particles once blood-borne may alter monocyte-macrophage 
function and activate circulating platelets with adverse effects on clinical 
outcomes. Previously it has been shown that inhalation of combustion-
derived nanoparticles results in increases in platelet-monocyte aggregation 
and thrombus formation in healthy volunteers. These combustion derived 
nanoparticles share structural similarities with engineered nanoparticles 
designed for intravascular infusion. This raises an obvious paradoxical 
question: can engineered nanoparticles designed for medical use mediate 
similar effects to combustion derived nanoparticles in susceptible 
populations?  
 
My thesis addresses this question and describes a series of complimentary 
experimental and clinical studies to investigate the effects of engineered 
nanoparticles on platelet function and thrombogenesis using commercial and 
clinically available nanoparticles. I found that cationic nanoparticles caused 
platelet activation and aggregation in vitro, whereas, anionic nanoparticles 
caused inflammation and up-regulated adhesion molecule ICAM-1 in 
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monocyte derived macrophages indicating that nanoparticles have different 
toxicological properties in different biological conditions. Using an ex vivo 
model of thrombus formation, the Badimon chamber, I observed that USPIO 
nanoparticles added to flowing native whole blood in an extra-corporeal 
circuit increased platelet rich thrombus formation under high shear conditions 
compared to saline control in healthy volunteers. These studies were 
repeated in patients with abdominal aortic aneurysms who received intra-
venous systemic infusions of USPIO to enhance MRI imaging. I 
demonstrated up-regulation in markers of platelet activation and more 
platelet rich thrombus formation in the Badimon chamber one hour following 
systemic delivery of USPIO. 
 
In summary I have demonstrated that medical nanoparticles influence 
platelet activation in patients with cardiovascular disease and have pro-
thrombotic effects in an ex-vivo model of in both healthy persons and 
susceptible patients. In light of this data and to ensure the safe future 
development of engineered nanoparticles for medical use platelet activation 
assays and follow-up monitoring of patients should be considered routine in 
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 Introduction Chapter 1 
 
Much of the following chapter has been adapted from Chapter 8, p139-156 
“Cardiovascular Effects” of the book “Adverse Effects of Engineered Nanomaterials” 
written by Jennifer B Raftis, edited by Nick Mills and Rodger Duffin. 
 
Cardiovascular Disease 1.1 
 
Cardiovascular disease is the most common cause of death worldwide in 
both men and women. As societies become more developed, and the 
standard of living improves, cardiovascular disease increases in prevalence 
as less people die early in life from communicable disease due to 
improvements in healthcare. Life expectancy also increases and 
cardiovascular disease is more common in older persons. Increasing 
knowledge and treatment of cardiovascular risk factors has led to a decline in 
mortality rates in developed countries however the problem continues to 










Atherothrombosis is a complex inflammatory disease and is classified 
according to plaque composition (van Gils et al. 2009). Plaque development, 
rupture and subsequent thrombosis involve a number of inflammatory 
processes including endothelial dysfunction, leukocyte recruitment and 
migration, platelet activation, matrix metalloproteinase (MMP) activity, and 
degradation of the fibrous cap resulting in plaque rupture and thrombosis 
(Slevin et al. 2008).  
 
The following image taken from Sanz and Fayad 2008 (Sanz and Fayad 
2008) depicts normal endothelium on the left and the development and 
rupture of an atherosclerotic lesion on the right hand side. 
 
 




Figure 1-1 Atherosclerotic Lesion Development  
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Cardiovascular Risk 1.1.2 
 
Successful therapies and strategies for prevention of cardiovascular disease 
are dependent on identification of individuals at risk using clinical risk scores 
based on age, sex, blood pressure, serum cholesterol and cigarette smoking 
(Viera and Sheridan 2010;Wang 2011). While these risk scores are used 
widely and identification of traditional risk factors is the basis of most primary 
prevention screening policies, these calculators are imperfect; the majority of 
persons presenting with an adverse cardiac event have no prior history or 
any established risk factors (Wang 2011). The converse is also true, many 
patients with risk factors do not go on to develop atherothrombotic disease or 
have an acute cardiovascular event. 
 
Cardiovascular risk is not a static entity and fluctuates hour to hour and day 
to day. There are many contributing factors to our cardiovascular risk some 
of which are:   
 Age 
 Gender 
 Physical Activity 
 Genetics 
 Diet 
 Blood Cholesterol 
 Blood Pressure 





 Air Pollution 
 
All these factors combine, at any one time, to determine how likely it is that 
an individual will suffer an adverse cardiovascular event. 
 
An alternative and perhaps preferable strategy would be to identify 
individuals with early atherosclerotic disease in an attempt to modify the 
course of the disease and prevent the clinical consequences of plaque 
rupture, thrombosis, and infarction. Clinical and experimental research has 
focused on the identification of novel biomarkers that could indicate the early 
development of atherothrombotic disease. Before a biomarker is introduced 
as a diagnostic tool in clinical practice, it must satisfy the following criteria: it 
must be highly specific, easy to measure, provide novel information about the 
disease, and reflect disease burden accurately helping the clinician decide on 
an appropriate course of treatment. These basic criteria are not easily met for 
a heterogeneous condition like atherothrombosis. Imaging strategies that 
target these pathological processes in atherosclerotic plaque development 
may provide more sensitive methods to monitor disease progression, permit 
early detection of the disease, and have a role in the assessment of 
treatment efficacy. The ability to identify plaque structure and function/activity 
would allow the clinician to identify those individuals at highest risk of plaque 
rupture. 
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 Nanoparticles 1.2 
Nanotechnology  1.2.1 
 
Nanotechnology aims at the development of nanoparticles (particles with at 
least one dimension less than 100nm; ENP) and other nanomaterials such as 
nanosurfaces and nanomatrices with novel properties not found in the same 
material in its bulk form. Nanotechnology is currently being applied in all 
manner of commercial industries to confer unique properties on products or 
improve those existing ones. One of the potentially most significant 
applications is in the field of medicine. A huge number of studies are 
underway to determine the usefulness of ENPs and nanosurfaces in a variety 
of medical fields and they are likely to have a big impact in areas such as 
diagnostics, medical imaging and treatment (Linkov et al. 2008) allowing for a 
movement towards personalised patient medicine. Concomitant with the 





Nanotoxicology assesses the potential risks of both naturally occurring and 
anthropogenic NPs; it serves to ensure the safety and continued 
development of nanotechnology whilst protecting consumers, workers and 
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the environment (Donaldson et al. 2004). The novel nature of ENPs is not 
taken into account under American, European or British medical product 
legislation. Whilst we may come to realise in the future that it is unnecessary 
to legislate ENP separately a more cautious approach seems warranted 
during early use. This should avoid unexpected outcomes and also increase 
public confidence in their safety when their use becomes widespread. 
Nanotechnology has advanced rapidly and is now a platform for many 
medical applications such as drug delivery (Wang et al. 2011), imaging 
(Yilmaz et al. 2011a) and diagnosis of disease (Hamzah et al. 2011). A 
number of questions have been raised about the safety of introducing large 
numbers of ENPs (Rosner and Auerbach 2011a) to potentially vulnerable 
patients (Donaldson and Seaton 2007). ENPs intended for clinical application 
should be rigorously tested with assessments taking into consideration the 
unique toxicology profile of nanoscale materials (Stone et al. 2007). The 
diversity of medical ENPs with respect to size, surface area, composition and 
surface properties, and the rapid pace of their development and 
commercialization, poses significant challenges to traditional toxicological 
paradigms (Gupta and Gupta 2005). With so many variables and no agreed 
standards for safety it may be difficult to fully characterise the effects of ENPs 
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Diagnostic and therapeutic applications of nanoparticles 1.3 
in cardiovascular disease 
 
ENPs are unique in terms of their size and structure. Their small size allows 
them to interact with the body at a molecular level and confers upon them a 
high surface area to volume ratio. They can be manufactured to have 
different shapes, sizes, structures, surface functionalization and coatings, 
allowing them to be specifically targeted to a biomarker of disease (Song et 
al. 2010). The ability to understand and manipulate the properties of 
nanomaterials will ultimately determine their usefulness in nanomedicine 
(Cormode et al. 2009). The following table, adapted from Kim et al 2010 (Kim 












 Nanoparticles and Atherosclerosis: Resolving the Paradox 
30 
 
Table 1-1 nanomaterials intended for clinical use 
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Nanomaterial synthesis has progressed rapidly in recent years and has 
generated complex state-of-the-art nanoscale structures with diverse and 
complex functionalities (Cormode, Skajaa, Fayad, & Mulder 2009). The ability 
to construct such nanomaterials has led to the development of multi-modal 
and multi-functional ENPs to facilitate magnetic resonance imaging (MRI), 
computed tomography (CT) and positron-emission tomography (PET) or for 
targeted drug delivery (Kim et al. 2011). The development of such ENPs has 
led to the terms “theragnostic” or “theranostic” to describe an ENP that can 
be used both for diagnostic and therapeutic applications (Cormode, Skajaa, 
Fayad, & Mulder 2009;Schladt et al. 2011).  
 
The application of nanotechnology to medical imaging is an exciting new 
frontier in medical science. To date only a handful of ENPs are used routinely 
in the clinic (Rosner and Auerbach 2011b;Weidner et al. 2011), but many 
more are in development or under investigation in clinical trials (Kim, Rutka, 
& Chan 2010). As a research tool, ENM are invaluable (Mulder et al. 2007). 
Unlike traditional imaging strategies, ENP based or molecular imaging 
modalities enable us to study the underlying mechanisms of disease in vivo 
to identify the biological, chemical and genetic factors contributing to the 
disease (McCarthy et al. 2010). On a simpler level, ENPs have been used to 
improve the effectiveness of current clinical diagnostic tools. For example, 
SPIONs are used as a contrast agent in patients undergoing magnetic 
resonance imaging (MRI) to improve spatial resolution.  
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Imaging as a diagnostic tool has gained importance over the years and is 
now indispensable in the clinic. Systems such as PET, single-photon-
emission computed tomography (SPECT), fluorescence reflectance imaging, 
fluorescence-mediated tomography (FMT), fibre-optic microscopy, optical 
frequency-domain imaging, will provide the future platforms for non-invasive 
molecular cardiovascular imaging. Comprehensive reviews of the 
nanomaterials in development for cardiovascular imaging are available 
elsewhere (Jaffer et al. 2006a;Jaffer et al. 2006b;Nahrendorf et al. 
2008;Nahrendorf et al. 2009a;Sosnovik et al. 2008). 
 
Superparamagnetic iron oxide nanoparticles 1.3.1 
 
In 1985, Stark et al used MRI to determine the quantitative relationship 
between relaxation rates and iron levels in patients with iron overload (Stark 
et al. 1985) and it was quickly deduced that the increase in T2 relaxation 
rates in these patients could be artificially replicated and used to provide 
contrast in MRI (Renshaw et al. 1986). MRI imaging has been used to 
assess the extent of damage after a myocardial infarct or to monitor 
peripheral vascular disease (Uppal and Caravan 2010). SPIONs were 
originally used to provide contrast when imaging liver (Fukukura et al. 2010), 
spleen (Beduneau et al. 2009) and lymph nodes (Weidner, van Lin, Dinter, 
Rozema, Schoenberg, Wenz, Barentsz, & Lohr 2011) as this is where these 
particles naturally accumulated. With improvements in ENP production iron-
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oxide ENPs were designed to be more biocompatible with increased 
circulation times to assist with MRI (Krombach et al. 2002a). Particle size and 
surface coating can be modified to target SPIONs to different sites. Larger 
particles, 50-150 nm in diameter, predominantly produce a signal decrease 
and are used as contrast media for imaging the liver and spleen. Smaller 
particles, less than 20 nm, are distributed more widely and can improve the 
identification of lymph nodes (Harisinghani et al. 1997;Harisinghani et al. 
2003) or assist in the characterization of vulnerable atherosclerotic plaque. 
SPIONs have been used to enhance plaque imaging in a number of 
experimental models of atherosclerosis (Briley-Saebo et al. 2008;Klug et al. 
2008;Klug et al. 2009;Sigovan et al. 2009), however the clinical studies 
published to date are less consistent (Morishige et al. 2010;Richards et al. 
2011;Tang et al. 2008;Yilmaz et al. 2011b).  
 
Macrophages are the most common target for molecular imaging agents as 
there is a large body of evidence implicating them in the disease and, as a 
naturally phagocytic cell; they tend to scavenge foreign material without 
much manipulation. Several experimental studies have demonstrated that 
SPIONs or ultra-small paramagnetic iron oxide ENPs (USPIONs) can localise 
to atherosclerotic plaques and can be used to evaluate its metabolic state 
(Klug, Gert, Thomas, Christan, Marco, Elisabeth, Volker, Rommel, Eberhard, 
Peter, & Wolfgang 2009;Kooi et al. 2003a;Richards, Semple, Macgillivray, 
Gray, Langrish, Williams, Dweck, Wallace, McKillop, Chalmers, Garden, & 
Newby 2011;Schmitz et al. 2001a;Trivedi et al. 2004). Targeted molecular 
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imaging has been shown to result in localisation of ENPs within macrophage 
in atherosclerotic plaque (Kooi, Cappendijk, Cleutjens, Kessels, Kitslaar, 
Borgers, Frederik, Daemen, & van Engelshoven 2003a;Ruehm et al. 
2001a;Trivedi et al. 2003a).  
 
Other applications of SPIONs include the assessment of myocardial 
perfusion (Jing et al. 2008;Krombach et al. 2002b) and characterisation of 
aortic aneurysms (Richards, Semple, Macgillivray, Gray, Langrish, Williams, 
Dweck, Wallace, McKillop, Chalmers, Garden, & Newby 2011). SPIONs with 
a modified coating have also been used in molecular imaging, such as 
receptor-directed imaging (Eck et al. 2010), cell labeling for in-vivo monitoring 
of stem cell migration (Thu et al. 2009), and in labelling gene constructs for 
localization in gene therapy studies (Zhao et al. 2010). 
 
Design and synthesis of SPIONs 1.3.2 
 
For molecular imaging purposes SPIONs need to be biocompatible, low-
toxicity, have a high magnetic moment, high colloidal stability, uniform 
particle size and the ability to bind various types of biological molecules 
(Lodhia et al. 2010a). The particle surface, functionalization or coating acts 
as the interface between the body and the core of the ENP often acting as a 
barrier to stabilise the core thus ultimately determining the reactivity and 
solubility of the ENP core (Mahmoudi et al. 2011a). Often the surface 
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monolayer is used to target the core molecule to a specific site of interest. 
Drug delivery to a specific area of the body without the associated systemic 
side effects is one of the most attractive attributes of a ENP- based drug 
delivery platform (Mahmoudi, Sant, Wang, Laurent, & Sen 2011a). Delivery 
of SPION’s to a specific region of interest or disease state is dictated by their 
surface functionalization (Uppal et al. 2011;Uppal & Caravan 2010). 
 
For the most part SPIONs are in development as MRI contrast agents, which 
relies on them having a high saturation magnetism value measured as 
electromagnetic units per gram (Lodhia, Mandarano, Ferris, Eu, & Cowell 
2010a;Lodhia et al. 2010b). This value will determine the overall 
effectiveness of the contrast agent. Relaxation rates are a measure of the 
ability of a contrast agent to enhance the relaxation rate of water protons 
(H1). SPIONs with high T2 values have faster relaxation rates.  Properties 
that affect the magnetisation value of a SPION include size and aggregation 
with the highest values occurring in particles between 6-20nm in diameter. 
When each particle is separate it will act independently, which increases the 
net magnetism per unit mass. The more particles aggregate the lower their 
magnetisation values and surface coatings are often used to prevent 
aggregation. 
  
Research focusing on understanding the various interactions of SPIONs with 
the glycocalyx and biomolecules in vivo (i.e. protein corona) may lead to 
novel SPIONs with optimum surface properties that might overcome the 
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problems of toxicity (see below) and permit more successful targeting 
(Mahmoudi et al. 2011b;Shaw and Murthy 2010). Examples of SPIONs in 
development or in clinical use are given below (adapted from Lodhia et al) 
(Lodhia, Mandarano, Ferris, Eu, & Cowell 2010a):  
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Particokinetics of parenteral delivery of nanomaterials 1.3.3 
for medical applications 
 
Toxicokinetic studies are intended to define parameters under which a 
xenobiotic is to be studied and the particle equivalent is particokinetics. Ideal 
mass balance particokinetics aims to have information that is comparable 
from one study to another defining the adsorption, distribution, metabolism 
and elimination (ADME) of the xenobiotic (Buchanan et al. 1997). Relative to 
the amount of literature available on the applications of ENPs in medicine, 
there is little in the way of particokinetic data concerning the fate of such 
particles following exposure (Lewinski et al. 2008). With ENP, not only do we 
have to consider whether the particles themselves are inherently toxic, but 
also how they interact with molecular structures and how, or if, they 
redistribute and clear from organs and tissues.   
 
When used in drug delivery, ENPs are often employed to increase specificity 
of drug delivery and improve persistence of the parent drug in the body (Li 
and Huang 2008). In a situation where the ENP increases drug circulation it 
is important to monitor particokinetics to predict potential parent drug toxicity 
and side effects which may be substantially altered once the drug is 
associated with a ENP (Li & Huang 2008). Characteristics of the ENP such 
as size, surface area, charge and surface chemistry as well as the method by 
which they are introduced (intravenous, inhalation, sub-dermal injection, 
 Nanoparticles and Atherosclerosis: Resolving the Paradox 
38 
 
ingestion into the gut etc.) determine the ultimate fate of the ENP once inside 
the body. Medical ENP themselves are usually made of materials deemed 
biologically safe and are generally not the drugs themselves, merely a 
delivery vehicle as is the case with drug-loaded liposomes. They may also 
serve as a means of visualising pathological processes and lesions in life as 
is the case with nanoparticulate contrast agents. The behaviour of ENP 
cannot be determined from their bulk properties since relatively low toxicity 
materials in their bulk form display novel properties, even toxicity, when 
presented in the nano-scale. Therefore it is very important to rigorously test 
nanomaterials composed of a material even if it has been found to be low 
toxicity in bulk form and in fact the nano-form may arguably be seen as a 
new materials with unknown properties. Kinetic studies of ENPs used in 
medicine have been carried out, but no single consensus has emerged on 
what determines their fate.  
 
1.3.3.1 Surface dependent distribution 
 
Surface characteristics are one of the main factors in determining whether or 
not a particle will be cleared by the recticuloendothelial system (RES) after 
intra-venous administration (Al-Jamal et al. 2009). When hydrophobic ENPs 
are injected intra-venously they are rapidly opsonised by blood serum 
proteins and cleared from the circulation by the RES resulting in significant 
losses from circulation. However this opsonisation can be limited by 
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alteration of the surface coatings of the ENPs. The most common method of 
prolonging circulation is conjugation of the ENP with polyethylene glycol 
(PEG) polymer, providing the particle with steric hindrance to opsonisation or 
phagocytosis (Li & Huang 2008) and allowing the ‘PEG-ylated’ form to 
remain in the circulation for much longer thus increasing their potential for 
interaction with blood components. A number of studies have demonstrated 
altered distribution patterns based on modification of the surface coating. He 
(He et al. 2008) compared three silica ENPs each with a different surface 
ligand attached, -OH, -COOH and PEG. The PEG-ylated particles showed 
longer circulation times and a reduced uptake by the RES. Beduneau 
(Beduneau, Ma, Grotepas, Kabanov, Rabinow, Gong, Mosley, Dou, Boska, & 
Gendelman 2009) covalently conjugated IgG molecules to the surface of 
SPIONs showing accelerated uptake by monocytes and enhanced retention 
in vivo without affecting monocyte viability. This technique could be very 
useful in the monitoring and tracking of disease progression. It is clear that 
surface modification has the ability to alter distribution and clearance patterns 
of ENPs in the body, with small changes in surface moiety resulting in big 
differences in behaviour of these particles in the body (van Tilborg et al. 
2008),  (Jayagopal et al. 2007). Berry (Berry et al. 2003) demonstrated the 
need for increased understanding of ENP-cell interactions and how quickly 
they can be altered through surface modification. In the study the same 
ENPs were made with either a dextran or albumin polymer coating which 
significantly altered the pattern of ENP uptake by fibroblasts. The dextran 
ENPs were endocytosed and caused eventual cell death, whereas the 
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albumin-coated particles showed only signs of partial endocytosis and 
induced cell proliferation. This demonstrates the need to determine particle 
and coating activity as a whole and recognition of particles coatings in 
ultimately determining biodistribution patterns and determine biological 
activity. 
 
1.3.3.2 Size Dependent Distribution  
 
Others have suggested that size determines the final location of particles 
injected into the bloodstream (De Jong et al. 2008). This is likely to be true to 
an extent but is probably most relevant in those with an underlying condition 
such as atherosclerosis. Normally, in a healthy individual, the endothelium is 
very effective at preventing extravasation of ENPs due to the presence of 
tight junctions between endothelial cells (<2nm). However when the 
endothelium is compromised, as is the case in atherosclerosis, the normally 
tight junctions become more permeable and could potentially allow passage 
of ENPs in to underlying matrix, with unknown consequences. The final 
destination of particles in the body has been reported to be directly related to 
their size, with larger particles, >100nm, accumulating in the spleen due to its 
discontinuous endothelium with large fenestrations. Smaller particles, 
<100nm, accumulate in the liver passing through the fenestrated endothelium 
and finally taking up residence in the underlying parenchymal cells. Kinetic 
studies with gold ENPs show a size-dependent pattern of distribution. A 
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study by De Jong (De Jong, Hagens, Krystek, Burger, Sips, & Geertsma 
2008) investigated a range of gold ENPs, administered intravenously in rats 
and found that biodistribution was dependent on particle size. The smallest 
particles (10nm) showing the most widespread organ distribution with 0.3% 
crossing the blood-brain barrier and high concentrations of all particles 
remaining in circulation after 24 hours, which could result in further 
accumulation in the organs. A similar study (Semmler-Behnke et al. 2008) in 
rats compared two particle sizes, both in the ultrafine range, 1.4nm and 18nm 
gold ENPs.  The clearance of 1.4nm gold occurred via the kidneys and 
hepatobillary system whereas no such clearance was observed for the 18nm 
particles. They also reported accumulation of the larger particles in the liver 
and spleen, whereas no such organ-specific accumulation was seen for the 
1.4nm particles.  
 
1.3.3.3 Localisation to Atherosclerotic Plaques 
 
Targeted molecular imaging has been shown to result in localisation of ENPs 
to atherosclerotic plaques (Kooi et al. 2003b),(Trivedi et al. 2003b), (Ruehm 
et al. 2001b). So it is known, with certainty that intravenously delivered ENPs 
deposit in the atherosclerotic plaque, but their ability to influence the 
atherosclerotic lesion development remains uncertain. Macrophages are the 
most commonly chosen target for molecular imaging as there is a large body 
of evidence implicating them in atherosclerosis and as naturally phagocytic 
 Nanoparticles and Atherosclerosis: Resolving the Paradox 
42 
 
cells they tend to internalise foreign material. A study by Amirbekian 
(Amirbekian et al. 2007a) showed that enhancements seen in MRI scans with 
macrophage scavenger receptor (MSR) targeted gadolinium micelles 
(100nm) were directly related to macrophage content of the atheromas 
whereas gadolinium uptake was not seen with untargeted Gd-micelles. A 
study by (Schmitz et al. 2001b) showed that carboxydextran-coated USPIOs 
accumulated in endothelial cells and macrophages within atherosclerotic 
plaques in rabbits and followed up this work with a clinical study (Schmitz et 
al. 2002). Trivedi (Trivedi, King-Im, Graves, Cross, Horsley, Goddard, 
Skepper, Quartey, Warburton, Joubert, Wang, Kirkpatrick, Brown, & Gillard 
2004) also showed accumulation of USPIO in carotid atheromas in 
macrophages in 7 out of 8 patients treated with Sinerem. The distinct 
pathologies of atherosclerotic plaques provide a highly sensitive way of 
imaging disease progression, allowing for early detection of the disease, and 
providing a useful tool in the assessment of the success of treatment. There 
is a clear need to develop a consensus on the ultimate fate and toxicity of 
intravenously administered ENPs and gain a better understanding of the 
mechanisms through which ENPs adversely affect cardiovascular outcomes.  
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Table 1-3 Size based ENP biodistribution 
 
(Hirn et al. 2011;Semmler-Behnke, Kreyling, Lipka, Fertsch, Wenk, 
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Nanoparticles and Cardiovascular Disease 1.4 
 
Adverse effects of combustion derived nanoparticles in 1.4.1 
cardiovascular disease 
 
There have been many epidemiological and experimental studies 
demonstrating the adverse health effects of PM10 with the majority of 
investigators identifying the ‘ultrafine’ or nanoparticulate component as the 
most toxic of airborne pollutants (;Donaldson et al. 1997;Geiser et al. 
2005;Mills et al. 2008b). These adverse effects are in the lungs, causing 
exacerbations of their condition in individuals with COPD and asthma and in 
the cardiovascular system, causing deaths and hospitalisations from heart 
attacks and strokes (Brook et al. 2002;Delfino et al. 2005;Mills et al. 
2007a;Mills et al. 2009). These studies have raised concerns about the 
potential for ENPs to exert similar adverse health effects. These 
cardiovascular effects are thought to be mediated by particle induced 
oxidative stress and inflammation leading to vascular dysfunction, impaired 
fibrinolysis, and changes in the autonomic regulation of heart rate and rhythm 
(Langrish et al. 2008;Mills, Donaldson, Hadoke, Boon, MacNee, Cassee, 
Sandstrom, Blomberg, & Newby 2009). In support of this contention, CDNPs 
have been shown to be prothrombotic (Mills et al. 2007b) and may contribute 
to the formation of atherosclerotic plaques. Whilst CDNPs differ greatly in 
chemical composition compared to ENPs they share similarities in other 
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characteristics considered toxicologically significant, such as size and 
surface area; It is therefore plausible that ENPs will exert similar pro-
inflammatory and pro-thrombotic effects, especially those manufactured for 
direct intravenous administration as a contrast agent in medical imaging 
(Donaldson 2006;Donaldson & Seaton 2007).  
Given the huge amount of published data implicating CDNPs in the 
pathogenesis of cardiovascular diseases (Donaldson et al. 2005) an 
understanding of the cardiovascular toxicology of ENPs intended for medical 
use is essential to ensure their safe future use.  
 
Toxicity of nanoparticles in cardiovascular disease 1.4.2 
 
It is not surprising that a number of recent reviews focusing on the effects of 
occupational exposure to ENM have raised concerns that they could have 
similar health implications as CDNP (Castranova 2011;Eisen et al. 
2011;Moller et al. 2011a). Resolution of these issues will require a 
collaborative approach between industry, government, academic 
researchers, and clinicians. In addition to occupational exposure to ENM the 
direct exposures to ENPs through medical use in susceptible populations is 
of immediate concern. ENM, unlike, pharmacological therapies are not 
routinely tested to determine their effect on the cardiovascular system prior to 
clinical use. All of these ENPs, not just those intended for the diagnosis and 
treatment of cardiovascular disease, have the potential to interact with cells 
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associated with disease progression. There have been no observational 
studies linking exposure to ENM and cardiovascular events, but a number of 
pre-clinical studies have reported that exposure to nanomaterials, directly or 
indirectly, can cause endothelial dysfunction and platelet activation, and may 
plausibly contribute to ischemic heart disease (McGuinnes et al. 2011;Sun et 
al. 2011;Zhu et al. 2010;Zhu et al. 2011a).   
The schematic diagram below identifies mechanisms and potential targets for 




Figure 1-2 Targets for ENPs after intravenous injection 
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In vitro studies 1.4.3 
 
Cardiovascular disease is a complex and dynamic process with many 
contributing factors and therefore a single in vitro model to study the adverse 
effects of ENM on cardiovascular system is unlikely to emerge. However, 
platelets, platelet-monocyte aggregation and the vascular endothelium have 
emerged as useful in vitro test systems, given their key role in the 
pathogenesis of coronary and ischemic heart disease (Neun and 
Dobrovolskaia 2011) (Bihari et al. 2010)  
 
Compatibility of ENPs with blood components is important and a number of 
studies have employed assays of erythrocyte haemolysis (Lu et al. 2009), 
platelet aggregation and activation (Radomski et al. 2005), and platelet-
leukocyte aggregation (McGuinnes, Duffin, Brown, Mills, Megson, MacNee, 
Johnston, Lu, Tran, Li, Wang, Newby, & Donaldson 2011). Direct and indirect 
toxicity to the cardiovascular system can be determined using cell lines with 
assays of oxidative stress, inflammation, and cell death (Dick et al. 2003). 
Whether observations from these in vitro models apply in vivo or in the clinic 
is uncertain, and in the absence of any standards for the assessment of the 
cardiovascular toxicity of ENM the role of in vitro assessments remain 
controversial. 
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Recent studies have shown that ENPs can interact with platelets causing 
activation, aggregation (McGuinnes, Duffin, Brown, Mills, Megson, MacNee, 
Johnston, Lu, Tran, Li, Wang, Newby, & Donaldson 2011;Miller et al. 
2009b;Radomski, Jurasz, onso-Escolano, Drews, Morandi, Malinski, & 
Radomski 2005). Surface charge has been shown to be a critical determinant 
in platelet-ENP activation (McGuinnes, Duffin, Brown, Mills, Megson, 
MacNee, Johnston, Lu, Tran, Li, Wang, Newby, & Donaldson 2011). When 
studying the impact of ENM on a complex multisystem disease it is important 
to take into consideration potential downstream, indirect effects as well as 
direct toxicity. Shaw et al (Shaw et al. 2011) demonstrated that CDNPs 
induce moderate toxicity and inflammatory effects on endothelial cells 
following direct treatment. These effects were, however, amplified when 
endothelial cells were exposed to conditioned supernatant from monocyte-
derived macrophages (MDMØ) exposed to CDNP due to the release of 
cytokines from CDNP -exposed macrophages. This approach utilising co-
culture and other techniques that model the secondary effects of CDNPs 
(Inoue and Takano 2010;Ishii et al. 2005;Porter et al. 2007), could be very 
useful in studying the cardiovascular effects of nanomaterials. Nanomaterials 
are increasingly being used in cell tracking to monitor disease progression 
(Jendelova et al. 2004;Jing, Yang, Duan, Xie, Chen, Li, & Tan 2008;Voura et 
al. 2004). It is no longer sufficient to assess the potential toxicity of ENPs on 
the cell carriers alone; it is essential that these cells do not become ‘time 
bombs’ capable of releasing pro-inflammatory mediators in a vulnerable 
atherosclerotic plaque.  
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In vivo studies 1.4.4 
 
In vivo studies carried out in susceptible animals have contributed 
significantly to our understanding of cardiovascular disease. In the ApoE 
knock-out mouse CDNP instilled into the lungs increases atherogenesis 
(Lucking et al. 2008;Tornqvist et al. 2007). Indeed ENM such as carbon 
nanotubes and TiO2 can accelerate plaque progression in susceptible animal 
models (Moller, Mikkelsen, Vesterdal, Folkmann, Forchhammer, Roursgaard, 
Danielsen, & Loft 2011a). Mills & Miller et al exposed healthy human 
volunteers to dilute diesel exhaust, pure carbon ENPs, filtered diesel 
exhaust, or filtered air, in a randomized double blind cross-over study 
demonstrating that the adverse vascular effects of diesel exhaust could be 
attributed mainly to the nanoparticulate component and not to the associated 
gaseous pollutants (Mills et al. 2011). Observations in vivo were replicated in 
vitro using wire-myography providing a rationale for testing the effects of 
ENM on vascular function before introduction to the clinic. 
 
Ex vivo studies 1.4.5 
 
Ex-vivo studies have been very informative in modelling the effects of CDNP 
on cardiovascular disease. They allow measurements to be taken in tissues 
or artificial environments outside the organism, but with as little as possible 
deviation from natural conditions with no risk to the patient. Ex-vivo 
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techniques have not been used widely to study the effects of ENM on the 
cardiovascular system due to the need for specialist equipment, training, and 
the high cost involved. However, given the potential to generate meaningful 
data in the near patient setting these systems are worthy of consideration. Ex 
vivo techniques also side-step possible ethical issues associated with 
exposing healthy or diseased populations to the unknown effects of ENPs. 
Traditional ex-vivo models have assessed the direct effects of CDNP in 
isolated vessels to assess vasomotor dysfunction. This chapter does not 
intend to review previous studies as they have largely focused on CDNP 
however this topic is very well covered by many comprehensive reviews 
(Moller, Mikkelsen, Vesterdal, Folkmann, Forchhammer, Roursgaard, 
Danielsen, & Loft 2011a) and the findings can be applied to the study of the 
adverse effects of nanomaterial (Moller et al. 2011b).  
 
As many medical ENPs in development are for use in populations considered 
particularly vulnerable, it would be desirable to model this ex vivo. The 
Badimon chamber is an ex vivo model of deep arterial injury and thrombus 
formation used previously to study the effects of diesel exhaust inhalation on 
thrombosis in man (Lucking, Lundback, Mills, Faratian, Barath, Pourazar, 
Cassee, Donaldson, Boon, Badimon, Sandstrom, Blomberg, & Newby 
2008;Lundback et al. 2009). The chamber permits an assessment of 
thrombus formation in whole native blood without the need for anti-
coagulants or exposure of the patient to the compounds being tested. While 
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principally used to assess the impact of novel antithrombotic agents it can be 
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The Paradox 1.5 
 
We are regularly exposed to nanoparticles from numerous sources both 
natural and anthropogenic. The effect of exposure to environmental particles 
has been widely studied with particular attention to the ‘ultrafine’ or CDNP (Li 
et al. 1997;Mills et al. 2008a). It is from such studies that most of our 
information pertaining to ENP toxicology has been extrapolated. Although 
CDNPs display significant differences in chemical makeup to ENPs they 
share similarities in characteristics considered toxicologically significant such 
as size and surface area. CDNP’s have been shown to be prothrombotic in 
man (Mills et al. 2007c) and directly contribute to the formation of 
atherosclerotic plaques in experimental models (Campen et al. 2010). These 
CDNPs share properties with ENPs intended for direct administration to 
patients. This raises an obvious paradox regarding the prothrombotic 
capabilities of ENPs, especially those manufactured for intravenous 
administration.  
 
It is therefore highly likely that exposure to some ENPs trigger acute 
cardiovascular events in those who are most vulnerable. I hypothesise that 
ENPs delivered directly into the blood will activate platelets and monocytes 
resulting in increased thrombosis. 
 
 





The primary aim is to evaluate the effects of engineered nanoparticles on 
platelet funtion and thrombosis.  The role of surface chemistry and charge in 
determining any prothrombotic effects was evaluated.  
 
The following specific  research questions are addressed:- 
 
 Do engineered nanoparticles directly induce platelet activation in vito? 
 
 Are the effects of engineered nanoparticles determined principally by: 
 particle  charge or surface chemistry? 
 
 Do engineered nanoparticles induce platelet activation and thrombus 
formation in an ex-vivo model of thrombus formation? 
 
 Do engineered nanoparticles delivered systemically through intra-
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 Nanoparticle Panel Chapter 2 
Abstract 2.1 
 
ENP characterisation is necessary to establish understanding and control of 
ENP synthesis and applications. For toxicological purposes knowing the 
parameters of what you are testing is essential for developing a structure 
activity relationship. This has proved difficult in ENP toxicology as no one 
characteristic; test or model has been shown to reliably predict toxicity. The 
ENPs selected for this study are a mixture of clinical and high-grade non-
clinical SPIONs and two charged polystyrene latex beads used as a model 
for the toxicity of positively or negatively charged ENPs. The significance of 
this study is to identify and establish the physical parameters of the ENPs in 
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Feraheme (AMAG pharmaceuticals) is an iron replacement product for the 
treatment of anaemia in adults. It is classified as a USPION and is coated 
with polyglucose sorbitol carboxymethylether (PSC). The overall colloidal 
particle size was 17-31 nm in diameter. Each mL of the colloidal Feraheme® 
contained 30 mg of elemental iron and 44 mg of mannitol. The formulation is 
isotonic with an osmolality of 270-330 mOsm/kg. The PSC coating, designed 
to delay release of the bioactive iron from plasma components until it has 
been cleared by the RES of the liver spleen and bone marrow. According to 
the manufacturer the iron is released from the iron-carbohydrate complex 
within vesicles in the macrophages and either enters the intracellular storage 
iron pool (e.g. ferritin) or transferred to plasma transferrin for transport to 
erythroid precursor cells for incorporation into haemoglobin. Feraheme® 
designed for delivery as an undiluted intravenous injection administered at a 
rate of up to 1mL/sec (30mg/sec) as a bolus injection. The recommended 
dose is an initial 510 mg intravenous injection followed by a second 510 mg 
intravenous injection 3 to 8 days later.  
 





SPIONs prepared by precipitation of iron oxide in the presence of dextran. 
Functionalized nanomag®-D-spio consists of about 55-85% (w/w) iron oxide 
in a matrix of dextran (40.000 Da). Nanomag®-D-spio are produced under 
controlled hygienic conditions. Hygiene areas are classified according to the 
ICH Q7A Good Manufacturing Praxis for drugs, the European GMP guideline 
for Good Manufacturing Praxis for drugs and investigational products, and 
according to DIN EN ISO 14644-1 for clean rooms and related clean room 
areas – Part 1: Classification of the air purity (ISO 14644-1:1999). All water is 
filtered through 0.2 µm filters and is routinely checked for microbiological 
contamination. The ENPs used in this project were Nanomag®-D-spio –NH2,  




Endorem™ (AMAG pharmaceuticals, Inc., Guerbet S.A.) was a black to 
reddish-brown aqueous colloid of superparamagnetic iron oxide associated 
with dextran for intravenous administration as a MRI contrast medium for the 
detection of liver lesions that are associated with an alteration in the RES. 
Endorem™ is taken up by macrophages, found only in healthy liver cells but 
not in most tumours. Tissues such as metastases, primary liver cancer, cysts 
and various benign tumours, adenomas and hyperplasia retain their native 
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signal intensity, so the contrast between normal and abnormal tissue is 
increased. The recommended dosage for Endorem™ is 4 mg/kg. Endorem™ 
is made up of dextran-coated iron oxide particles with a size distribution 
between 120 and 180 nm according to the manufacturer and an iron 
concentration of 0.2 mol/l. Before Endorem™ received approval in Germany 
and other European countries, clinical trials were performed in Japan, the 
USA, and Europe. At a dose of 10 micromole Fe/kg (Japan, USA) and 15 
micromole Fe/kg (Europe). 
 
Polystyrene Latex Beads 2.2.4 
 
Polystyrene latex ENPs has various applications in research. In this study 
they were used as model ENPs to assess the effects of charge on toxicity. 
 
Carboxylated Beads 2.2.5 
 
Polybead® Carboxylate Microspheres 0.05μm are monodisperse polystyrene 
microspheres that contain surface carboxyl groups. These microspheres are 
packaged as 2.5% solids (w/v) aqueous suspensions. 
 
Aminated Beads 2.2.6 
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Latex beads, amine-modified polystyrene, fluorescent blue are monodisperse 
polystyrene microspheres that contain surface amine groups. These 
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Materials and Methods 2.3 
 
Particle Sizing 2.3.1 
 
All ENPs were sized by dynamic light scattering (DLS) with a 90 plus Particle 
Size Analyzer (Brookhaven Instruments Corporation). All ENPs were 
suspended in sterile water (Milli-Q Academic, Millipore, MA, USA), water with 
10% human serum, saline (Baxter Healthcare, Eng) and saline with 10% 
human serum at 1mg/mL and bath sonicated (Fisherbrand FB11002, 40 kHz) 
for 5 minutes prior to sizing. ENPs were further diluted 1:300 in sterile water 
or saline, as appropriate, prior to measurement. Solutions were adjusted to 
give a count rate of between 50-300kcps (kilo counts per second). 
 
Zeta-Potential  2.3.2 
 
The electrophoretic mobility or zeta potential of the sample was measured in 
a 1 mL clear zeta potential cuvette (DTS1060, Malvern) using a Malvern 
Zetasizer Nano-ZS according to the manufacturer’s recommendations and 
converted into the zeta potential by applying the Henry equation. The data 
were collected and analysed with the Dispersion Technology software 4.20 
(Malvern) producing histograms for the particles size as a number distribution 
or diagrams for the zeta potential as a distribution versus total counts. ENPs 
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were measured in water, water with 10% human serum, saline, and saline 
with 10% human serum. 
 
Transmission Electron Microscopy 2.3.3 
 
ENPs were suspended in sterile water (Milli-Q Academic, Millipore, MA, 
USA) at a concentration of 1mg/mL and sonicated for 5 minutes (Fisherbrand 
FB11002, 40 kHz). ENPs were further diluted 1:100 in sterile water. A drop 
(5µL) of this solution was loaded onto a 1 x 2 mm copper slot grid with a 
support film of Formvar/carbon (Agar Scientific, Essex, UK), covered and 
allowed to dry overnight @37˚C and visualized using a Philips CM120 
transmission electron microscope (TEM). 
 
Electron Paramagnetic Resonance 2.3.4 
 
Electron paramagnetic resonance (EPR) was utilized to detect intrinsic free 
radical generation from the iron oxide ENPs used in this study. An EPR 
spectrometer (Miniscope MS200, Magnettech GmBH, Berlin) was used to 
detect electrons present in free radicals via alterations in electromagnetic 
energy. Due to the volatility of these free-radicals a spin-trap is used to 
capture them prior to measurement. There are many spin-traps available 
depending on the free-radical to be measured. In this case 1 hydroxyl-
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2,2,6,6-tetramethyl-4-oxo-piperdine (Tempone-H; Alexis Co., Bingham, UK) 
was chosen to detect the generation of superoxide, peroxyl and peroxynitrite 
radicals (Miller et al. 2009a). The spin-adduct formed results in a 





Figure 2-1Tempone-H spectrum  
Samples were prepared at 50µg/mL in Hank’s Balanced Salt Solution 
(HBSS) (PAA Laboratories Ltd., UK) with the addition of 1mM Tempone-H 
and incubated for 1-hour at 37˚C. Positive (Pyrogallol 100µM) and negative 
(HBSS) controls were employed to show both that the EPR spectrometer 
was calibrated and the HBSS used was not contaminated. All samples were 
transferred immediately after incubation to glass micropipettes (intraMARK 
BLAUBRAND, rand GmBH +CO KG, Wertheim, Germany) sealed with 
Cristaseal™ (VWR International, Lutterworth, UK). The spectrometer was 
set-up using the following settings: microwave frequency, 9.3-9.55 Hz; 
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microwave power, 20 mW; modulation frequency, 100 kHz; modulation 
amplitude, 1500mG; Centre field, 3365 G; sweep width, 50 G; sweep time, 
30 sec; number of passes, 1. The EPR intensity was measured at 60 minutes 
and a numerical value (arbitrary scale) calculated using Miniscope software 
(version 6.51; Magnettech, Berlin, Germany) based on the area under the 
curve of the first event of the first three-event spectrum generated as 
previously described (Miller, Borthwick, Shaw, McLean, McClure, Mills, 
Duffin, Donaldson, Megson, Hadoke, & Newby 2009a). 
 
Nanoparticle Protein Affinity 2.3.5 
 
ENPs were incubated with human serum, made by re-calcification of platelet 
rich plasma, for 30 mins @37˚C. ENP serum suspensions were centrifuged 
@14,000g for 10 mins, the supernatant removed and ENP pellets washed 
with 1 mL deionised (DI) water. The wash cycle was repeated 5 times after 
which proteins associated with the ENP pellet were reduced using the 
NuPAGE® Novex® Bis-Tris Mini Gel system (Invitrogen™, life 
technologies™) according to manufacturer’s instructions. Samples were 
diluted 1:12 in DI water before loading in the gel. Post- staining of the protein 
gels was carried out with SilverXpress® Silver Staining Kit as per 
manufacturer’s instructions. Gels were assessed qualitatively for ENP-protein 
binding. 
 





Data are expressed as mean ± SEM unless otherwise stated. Statistical 
analysis was performed with GraphPad Prism (GraphPad Software, La Jolla, 
CA, USA) using one-way ANOVA Dunnett’s test as appropriate to compare 





















Table 2-1 Commercially Available ENPs used in the studies 

































USPIO-COOH  20 Dextran—COOH Micromod 
USPIO-NH2  20 Dextran-NH2 Micromod 
Polystyrene Beads  Latex 50 COOH Polysciences 
 Latex 50 NH2 Sigma Aldrich 
 
 All ENPs were chosen for their current and potential use in nanomedicine. A 










 Nanoparticles and Atherosclerosis: Resolving the Paradox 
65 
 
Table 2-2 ENP characteristics measured in-house. 







































































Poly-NH2 25.76±1.909 0.079±0.149 12.10±1.04 -10.80±0.60 48.93±0.77 
 
ENP size was measured in saline with 10% human serum. ENP size 
correlated well with the published manufacturer’s sizes. ZP is a measure of 
the electrophoretic potential of a particle in a solution. As ZP is heavily 
dependent on the solution in which the ENP is suspended it was important to 
measure the value in a biologically relevant fluid. Here ZP was measured in 
water and saline with or without human serum. ZP varied widely depending 
on the solution in which they were suspended, the addition of serum greatly 
reducing the ZP most likely due to the adsorption of protein (which are 
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negatively charged), onto their surfaces. All ENP had a negative zeta 
potential in water and water with 10% serum apart from the aminated beads. 
In the slightly acidic saline mimicking inter-lysosomal conditions the 
negatively charged ENP were less negative than when measured in water 
whereas both the aminated ENP were positively charged. All ENP were 
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Figure 2-2  Inherent free-radical generation of ENP  
 
 
Unpaired electrons on the surface of the ENPs were measured using EPR. 
The aminated (USPIO-NH2) and carboxylated (USPIO-COOH) iron oxide 
ENPs showed significant generation of free radicals superoxide, peroxyl and 
peroxynitrite. Data is mean±SEM, n=3-5. Pyrogallol is a positive control and 
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Figure 2-3 Transmission Electron Micrographs of Iron-Oxide ENPs 
Transmission electron micrographs of iron oxide 
ENPs on copper grids were imaged to determine 
the morphology and aggregation state of the 
ENP. All ENP were well dispersed but appeared 
to be made up of aggregates of much smaller 
ENP Feraheme (A) 50nm scalebar, Endorem (B) 
scale bar 100nm, Nanomag-NH2 (C) scale bar 























Figure 2-4 Protein Binding to ENPs 
 
Gradient gel electrophoresis of protein attached to ENP surface after a 20min 
incubation in human serum.  It appears that whilst all the ENP bound serum 
proteins the quantity was dependent on the surface functionalisation. The 
unmodified and carboxylated ENPs seemed to bind more proteins from the 
















Many types of ENPs are being tested for use in medical applications, 
particularly as platforms for imaging and drug delivery. For these 
applications, cellular uptake is usually a prerequisite and is dictated by a 
number of factors including size and surface characteristics such as charge. 
The different uptake preferences of phagocytic and non-phagocytic cells for 
cationic and anionic ENPs may influence the efficacy and selectivity of ENPs 
for drug delivery and imaging (Yang et al. 2012). 
 
SPIONs or ultrasmall SPIONs were chosen for this study as they are 
currently the most widely used ENP in a clinical setting and their use will only 
become more widespread in the future. Like most ENPs SPIONs can be 
produced in tight size ranges and specific functionality. Though not used 
clinically at the moment many functionalized SPIONs are in development for 
clinical use (Lamanna et al. 2011;Maity et al. 2012;Yang et al. 2011) in an 
attempt to target an area of interest e.g. atheroma (Michalska et al. 2012), 
instead of relying on passive uptake. This will be achieved through accurate 
chemical modification of the ENP surface and understanding the nano-bio 
interface. ENPs and their interaction with their biological structures, leading 
to the formation of a corona, is a huge area of research and is not addressed 
comprehensively in this study but as with all researchers studying the toxicity 
of ENPs the properties considered most like to confer toxicity were 
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measured, including;  size, charge, free-radical generation and protein 
binding.  
 
All iron oxide ENPs used in this study were considered low toxicity (Appendix 
I: Cytotoxicity). This study shows the effect of choice of suspension liquid is 
critical when determining the zeta potential of ENPs. This is not a new finding 
(Cho et al. 2012) but highlights the need to test ENPs in a relevant solution. 
Medical ENPs will not be delivered to the patient in water as it is not 
physiological and are much more likely to be delivered in saline, as is the 
case with Endorem™ or undiluted as supplied in a sugar/carbohydrate 
solution, e.g. mannitol, as is the case with Feraheme®.  
 
Electrostatic forces have been shown in some case to govern the 
internalization of viruses (Taylor and Sansom 2010). It could be hypothesized 
that due to the similar physical, size, characteristics ENP entry into cells 
could be influenced by the same forces. Both positively and negatively 
charged ENPs bind serum and albumin, but affinity differs between surfaces. 
In this study both of the positively charged ENPs bound protein to a lesser 
extent than the unmodified and carboxylated ENPs. Similar findings have 
been previously reported (Jin and Kim 2012) and may account for the 
increased cellular uptake and increased cytotoxicity displayed by the cationic 
ENPs (Appendix I&II) as their positively charge surfaces are not masked and 
free to interact with negatively charged cell membranes. Some have 
suggested positively charged ENPs cause pores to form in cells mediating 
 Nanoparticles and Atherosclerosis: Resolving the Paradox 
72 
 
their uptake and cytotoxicity (Frohlich 2012). A recent review, by FrÖlich 
2012,  summed up ENP uptake suggesting that cationic surface charge 
correlates with higher cellular uptake and greater cytotoxicity in non-phago-
cytic cells; cause plasma-membrane disruption and cell death whereas 
anionic ENPs are more easily ingested and are more cytotoxic to phagocytic 
cells such as macrophages. It was clear from this study that differently 
charged ENPs adsorbed serum proteins to different degrees. ENP-protein 
interactions are important if we are to make ENPs with specificity for 
particular sites within the body. From a chemistry point of view functionalising 
the ENP surface is not a major hurdle. Trying to design an ENP to target a 
specific area of the body through surface functionalisation without the homing 
molecules becoming masked by self-proteins will be the next big challenge in 
nano-medicine. 
 
The spin-trap tempone-H was used to monitor free radical generation at the 
surface of the ENPs. Iron is essential for many biological processes but too 
much or too little in ionic form can in turn lead to disease.   The body is good 
at dealing with an excess of iron in its elemental form but ENPs pose a 
longer term risk as they are retained and have the potential to produce free 
radicals as seen in this study which in turn can lead oxidative stress.  The 
aminated and carboxylated iron oxide ENPs showed significant generation of 
free radicals superoxide, peroxyl and peroxynitrite.  The functionalisation may 
disrupt the surface of the ENPs making them more reactive and prone to 
spontaneous free-radical generation. It has previously been shown in our 
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group that the polystyrene ENPs used in this study do not generate free 
radicals (McGuinnes, Duffin, Brown, Mills, Megson, MacNee, Johnston, Lu, 
Tran, Li, Wang, Newby, & Donaldson 2011) but have significantly different 
toxicological profiles based on their surface derivitisation. 
 
The following studies discuss the toxicity and biological effects of the ENPs 
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This study was designed to test the hypothesis that ENPs can cause platelet 
activation and induce an inflammatory state in monocyte derived 
macrophage cells (MDMØ) in vitro. Blood from healthy volunteers (n=5-10) 
was mixed with increasing concentrations of SPIO, USPIO, USPIO-NH2, 
USPIO-COOH, Poly-NH2 and Poly-COOH nanoparticles (described in 
chapter 2). Blood was analysed by flow cytometry for the following markers of 
platelet activation: platelet-leukocyte aggregation, platelet surface p-selectin, 
platelet surface glycoprotein IIb/IIIa via PAC-1 binding. Platelet response to 
agonists TRAP-6 and Thrombin was determined by pre-treating platelets with 
SPIO, USPIO-NH2 and USPIO-COOH using flow cytometry and calcium 
influx respectively. Poly-NH2 beads significantly activated platelets in all 
assays tested as did USPIO-NH2 nanoparticles Pre-treatment of platelets 
with all ENPs increased the sensitivity to TRAP-6, as measured by platelet 
surface p-selectin and PAC-1 binding, and thrombin, measured by calcium 
influx, suggesting that ENPs induce a hyper-reactive state.  
 
 Monocyte derived macrophages (MDMØ) isolated from human blood (n=4) 
were treated with SPIO, USPIO, USPIO-NH2, USPIO-COOH and assessed 
 Nanoparticles and Atherosclerosis: Resolving the Paradox 
75 
 
for inflammatory responses and ENP uptake. USPIO-COOH significantly 
increased levels of IL-8 pg/mL in cell culture supernatants over a 72-hour 
period as well as intercellular adhesion molecule ICAM-1. None of the other 
ENPs had an effect on MDMØ. Engineered nanoparticles with differing 
surface chemistries activated platelets and induced a pro-inflammatory state 






















As described in chapter one the paradox which exists between CDNPs 
contributing to CV risk and ENPs that are in development for the diagnosis 
and treatment of cardiovascular disease is one which needs to be resolved to 
ensure the safe continuation of their use in a clinical setting. Though the 
exact mechanisms by which CDNP mediate their adverse effect is unclear it 
has recently been established that it is the NP component that is driving the 
effect (Mills, Miller, Lucking, Beveridge, Flint, Boere, Fokkens, Boon, 
Sandstrom, Blomberg, Duffin, Donaldson, Hadoke, Cassee, & Newby 2011).  
 
Thrombosis plays a central role in the pathogenesis of atherothrombotic 
disease. As well as contributing to initiation of disease, thrombosis at the site 
of a disrupted under coronary flow can cause vessel occlusion, resulting in 
an infarct or coronary event. Platelets are the key players in thrombosis and 
anti-platelet therapy is common in the treatment of cardiovascular disease 
(Grove 2012) ameliorating to some extent both platelet-platelet adhesion and 
platelet-leukocyte interactions. It has been shown previously that exposure to 
diesel exhaust increases platelet activation and enhances thrombus 
formation in the Badimon chamber (Lucking, Lundback, Mills, Faratian, 
Barath, Pourazar, Cassee, Donaldson, Boon, Badimon, Sandstrom, 
Blomberg, & Newby 2008).  
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Increasingly platelet-leukocyte binding, platelet-monocyte in particular, has 
been shown to be a sensitive marker of platelet activation and inflammation 
(Passacquale et al. 2011). Inflammation and atherothrombotic disease have 
been well documented (Libby et al. 2002) and anything that increases the 
inflammatory burden within a system could have adverse cardiovascular 
effects. Previous work has suggested that ENPs can activate platelets based 
on their surface charge (Jones et al. 2012b) and induce inflammation in cells 





I hypothesise that ENPs (described in chapter 2) can activate platelets in 
vitro and induce an inflammatory state in MDMØ cells dependent on their 




 To test the effects of surface chemistry and charge on platelet 
aggregation and activation in response to ENPs. 
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 To determine whether ENPs increase platelet sensitivity to known 
agonists TRAP-6 and thrombin. 
 
 To determine whether ENP can induce a pro-inflammatory state in 
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Materials and methods 3.3 
Nanoparticle Panel 3.3.1 
Table 3-1Panel of Nanoparticles used in in Vitro studies 























USPIO-COOH  20 Dextran—COOH Micromod 
USPIO-NH2  20 Dextran-NH2 Micromod 




50 COOH Polysciences 
Poly-NH2 Latex 50 NH2 Sigma Aldrich 
 
Blood sampling 3.3.2 
 
Healthy non-smoking volunteers participated in this study. Subjects taking 
regular medication or with inter-current illness were excluded. The study was 
performed with the approval of the local research ethics committee, in 
accordance with the Declaration of Helsinki, and with the written informed 
consent of each participant. Blood was drawn by clean venepuncture of a 
large antecubital vein using a 19-gauge needle. Care was taken to ensure a 
smooth blood draw without venous stasis. The first 2ml was discarded and 
blood was taken without a tourniquet. Unless otherwise stated, blood was 
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collected into tubes containing the direct thrombin inhibitor, D-Phenylalanine-
L-prolyl-L-arginine chloromethyl ketone (PPACK, Cambridge Biosciences). 
Tubes were gently inverted to ensure mixing of whole blood with 
anticoagulant. 
 
Platelet leukocyte binding 3.3.3 
 
Immunolabelling and flow cytometry were performed in whole blood to avoid 
centrifugation and washing steps, which can lead to artifactual platelet 
activation (Harding et al. 2007). Aliquots of whole blood (60μl) were 
incubated with a suspension of ENPs at 7-times final concentration (20µl) 
and antibody cocktail (anti-CD14-R-phycoerythrin(PE), anti-CD42a- 
Fluorescein isothiocyanate (FITC), anti-CD16-APC(Allophycocyanin) (60µl) 
for 25-minutes (mins) at room temperature; samples were fixed and red 
blood cells lysed by the addition of 1.5mls FACS-Lyse solution (Becton 
Dickinson) unless otherwise stated. Isotype matched controls were used to 
set the monocyte and neutrophil gates. Samples were analysed using a 
Becton-Dickinson FACS Calibur flow cytometer and data analysed using 
FlowJo version 7.5 (Treestar, Oregon, USA).  All samples were analysed 
within 24 hours (hrs) unless otherwise stated. Monocytes were identified 
based on their forward and side scatter characteristics and then by triggering 
on FL-2 to identify CD14-PE positive monocytes and exclude large granular 
lymphocytes. For each measurement a minimum of 2,500 monocytes were 
 Nanoparticles and Atherosclerosis: Resolving the Paradox 
81 
 
collected. Platelet-monocyte aggregates were defined as CD14/CD42a 
positive cells. Neutrophils were identified based on forward and side scatter 
characteristics and triggering on the FL-4 channel. Platelet-neutrophil 
aggregates were defined as CD16/CD42a positive cells. All results are 
expressed as percentage of +ve events as previously described (Harding, 
Din, Sarma, Jessop, Weatherall, Fox, & Newby 2007). 
Plot A shows gating of monocytes based on their characteristic side and 
forward scatter. CD14+ monocytes were then selected from this gate shown 
in plot B. Plot C Fl2/Fl1 shows cells that stained with FITC-CD42a antibody 
and Pe-CD14 antibody Plot shows cells in the FL1 positive FL2 positive 
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Plot A shows gating of neutrophils based on their characteristic side and 
forward scatter. CD16+ neutrophils were then selected from the gate shown 
in plot B. Plot C Fl2/Fl1 shows cells that stained with FITC-CD42a antibody 
and Pe-CD16 antibody Plot shows cells in the FL1 positive FL2 positive 
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Platelet activation 3.3.4 
 
Immunolabelling and flow cytometry were performed in whole blood. Aliquots 
of whole blood (5µl) were incubated with a suspension of ENPs (10µl) at 2.5-
times final concentration and antibody cocktail CD42b-APC , CD62-p- (PE) 
and PAC-1- fluorescein isothiocyanate (FITC)  (BD Pharmigen) (10µl) for 25 
mins at room temperature and fixed with 800µl 1% paraformaldehyde (PFA). 
Samples were analysed using a Becton-Dickinson FACS Calibur flow 
cytometer with platelets gated by characteristic forward and side scatter 
properties and CD42a expression using appropriate isotype controls. The  
CD14/CD42a +ve, aminated bead treated populations were sorted into 1ml of 
medium. A further 5ml of PBS Phosphate Buffered Saline (Sigma Dorset, 
UK) was added to each tube and the samples were centrifuged at 1200rpm 
for 10 minutes. The cells were re-suspended in 50µl of PBS, which was then 
transferred to a slide and allowed to dry overnight in the dark, prior to being 
mounted in Moviol and viewed by Confocal microscopy Zeiss LSM Confocal 
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Platelet Hyper-reactivity 3.3.5 
 
Flow Cytometry 3.3.6 
 
Immunolabelling and flow cytometry were performed in platelet-rich plasma 
(PRP) derived from whole blood by centrifugation (Mistral 3000i) (200 g) 
without brake or acceleration for 20 mins. Platelet rich plasma was incubated 
with ENP for 10 mins on an orbital shaker. Thrombin Receptor Activating 
Peptide-6 (TRAP-6) was then added to each sample at a final concentration 
of 10µM. Samples were incubated with antibody cocktail (CD62-p-PE/PAC-1-
FITC) (10µl) for 20 mins and fixed with 500µl of 1% PFA. Platelets were 
gated based on characteristic forward and side scatter properties. 
 
Calcium influx 3.3.7 
 
Washed platelets (WP) were derived from PRP by centrifugation (1200 g, 10 
mins) in the presence of 300 ng/ml prostacyclin (PGI2) to prevent activation. 
WP were resuspended in PGI2-free HBSS buffer (without calcium and 
magnesium) and Fura-2 acetoxymethyl ester (Fura-2 AM; 2 mM), and 
incubated at 37°C for 30 mins. Following incubation, platelets were diluted to 
their original volume with HBSS, PGI2 added (300 ng/ml), and the mixture 
centrifuged (1200 g, 10 min). The supernatant was aspirated and discarded 
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to remove excess extracellular Fura-2 AM, and the loaded platelets re-
suspended in HBSS buffer to the original volume. All fluorescence 
measurements were obtained using a Perkin-Elmer LS50B luminescence 
spectrometer (Perkin Elmer, Berkshire, U.K.). Fluorescence was measured at 
371C, with excitation wavelengths of 340 and 380nm and an emission 
wavelength of 510 nm. Aliquots (1 ml) of Fura-2 AM loaded WP were 
equilibrated at 37°C before the addition of SPIO to a final volume of 50 µg/ml  
and 25 µg/ml; platelet nanoparticle mixtures were co-incubated  for 5 min. At 
5 min platelets were diluted with 2 mL HBSS with Ca2+/Mg2+ at 37°C and 
10µl of thrombin was added to a final concentration of 1 U/mL and 
fluorescence monitored over a 5 minute period. 
 
Platelet Aggregometry 3.3.8 
 
Aggregometry was carried out based on a method adapted from Armstrong 
et al 2009 (Armstrong et al. 2009). Blood was taken as described and 
centrifuged at 135g for 15mins to prepare PRP. PRP was maintained at 37°C 
throughout all experiments and was used within 3 hours of collection. Platelet 
poor plasma (PPP) was prepared by further centrifugation at 13,000g for 15 
mins. ENPs were prepared in 0.9% saline to four times the desired final 
concentration and added to a 96 well plate. 75µl PRP was added to the wells 
of the 96-well plate which was then immediately placed in a Biotek, Synergy 
HT plate reader set to read absorbance at 605nm every 30s for 16min 
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between vigorous shaking at 37°C. Changes in absorbance were converted 
to % aggregation by reference to the absorbance’s of PRP only and PPP-
ENP control readings.  TRAP-6 was used as a positive control. Digital 
images of aggregates were taken with a Cannon Powershot A640. 
% Aggregation = 100 - [(PRP – PPP.ENP control)/ (PRP-PPP)*100] 
 
Monocyte isolation 3.3.9 
 
Citrated whole blood was centrifuged (200 g; 20 min) and PRP aspirated. 
Leukocytes were separated from erythrocytes by dextran sedimentation and 
then further divided into peripheral blood mononuclear cells (PBMC) and 
granulocyte populations by centrifugation through a discontinuous Percoll® 
(Pharamcia, UK) gradient (720 g; 20 min). PBMC were harvested at the 
55:68% interface and re-suspended in phenol red free Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with penicillin and streptomycin 
(both 100 U/mL). Enrichment for monocytes was performed by selective 
adherence to 48-well (2x106 cells/well) tissue culture plates for one hour 
(37°C; 5% CO2). Adherent monocytes were washed three times in 
phosphate buffered saline (PBS) and differentiated into MDMØ for 5 days in 
IMDM containing 10% autologous serum prepared by recalcification of PRP. 
Medium was replaced every 2-3 days.  
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Monocyte derived macrophage 3.3.10 
 
Flowcytometry was used to determine cell viability and intracellular adhesion 
molecule (ICAM-1) expression in MDMØ. An anti-human CD54-APC antibody 
(Biolegend®) was used to stain MDMØ for ICAM-1. Following treatment with 
ENP or media only, untreated media only control cells (and their 
supernatants containing any non-adherent cells) were removed from tissue 
culture plates using cell detachment solution (Accutase™:Innovative Cell 
Technologies, Inc.). Recovered cell suspensions were incubated for 20 min 
with anti-human CD54, washed in PBS, and resuspended in HBSS 
containing prior to analysis by BD Fortessa flow cytometer (Beckman 
Coulter, USA) equipped with DIVA data acquisition software. ICAM-1 
expression was defined as the mean fluorescent intensity of APC.  
 
Cytokine analysis 3.3.11 
 
MDMØ supernatants (cell-free) were collected, clarified by centrifugation to 
remove any remaining ENP (13,000 g; 10 min) and analysed by enzyme-
linked immunosorbant assay (ELISA) for cytokine content as described 
below. Interleukin 8 (IL-8) concentrations were measured by ELISA (R&D 
Biosciences, UK) according to the manufacturer’s instructions in MDMØ cell 
supernatants. Briefly, cell culture supernatants were harvested, clarified by 
centrifugation, frozen immediately and stored at -70°C until analysed. Optical 
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densities were recorded by Dynatech MXR microplate reader (Dynatech 
Laboratories; USA), and the concentration of each cytokine calculated from a 
standard curve produced from serial dilutions of the appropriate cytokine. All 
standards and samples were assayed in duplicate.  
 
Confocal microscopy MDMØ 3.3.12 
 
Monocytes were isolated as above and added to an 8-well chamber slide 
(NUNC) at 4x106 cells/mL. Cells were allowed to differentiate for 5-6 days as 
above. MDMØ were treated with ENP suspensions made up in IMDM with 
10% autologous serum for 24hrs. Cells were washed three times with PBS 
then fixed in ice-cold 100% methanol for 10 mins at -20°C. Excess methanol 
was removed and cells were permeabilized with ice-cold acetone for 1min at 
-20°C. Cells were blocked with 1% bovine serum albumin in PBS for 1hr 
before staining with anti-CD54-APC antibody (20µl per million cells) for 1hr. 
Cells were washed three times with PBS, dried, and mounted with 
vectashield-DAPI mounting media before viewing with a Leica SP5 confocal 
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Electron microscopy 3.3.13 
 
NP uptake by MDMØ was assessed using transmission electron microscopy 
(TEM). MDMØ were isolated and plated as described above on plastic 
coverslips (Thermanox®; Nunc, USA) in 24-well plates. Following NP 
exposure (100µg for 24hrs), coverslips were removed and fixed for 1-2hrs in 
0.1 M sodium cacodylate buffer containing 3% glutaraldehyde. Coverslips 
were then fixed in 1% osmium tetroxide, embedded in araldite resin and cut 
into ultra-thin sections (60 nm thick) before viewing in a Philips CM12 




Data are expressed as mean± SEM unless otherwise stated. Statistical 
analysis was performed with GraphPad Prism (GraphPad Software, La Jolla, 
CA, USA) using one-way ANOVA with post-hoc Dunnett’s compare ENP 










Nanoparticles  3.4.1 
 
The nanoparticles used in this study were chosen for their relevance to 
clinically used ENP (see chapter 2). A range of doses were selected from 
500µg/mL to 62µg/mL. The doses may seem high but they were chosen to 
encompass realistic final blood concentrations and maximal point of injection 
concentrations. As this is primarily a toxicological safety study the top doses 
are beyond what a patient would be exposed to clinically.   
 
Platelet Activation 3.4.2 
 
The most striking effects on platelet-leukocyte binding were seen with the 
positively charged ENPs. Both the Poly-NH2 and the USPIO-NH2 caused 
significant increases in platelet-monocyte (Fig 3-3, Fig 3-4) and platelet-
neutrophil aggregation (Fig 3-5, Fig 3-6). No such increases were seen after 
treatment with either the un-functionalised or the carboxylated ENPs 
suggesting it is most likely an effect of the positive charge. Confocal 
microscopy images of whole blood treated with aminated beads revealed 
positively charged NP aggregated with platelets and bound to monocytes. 
Platelet surface p-selectin, which mediates platelet-leukocyte binding through 
binding PSGL-1, was significantly increased by the Poly-NH2 (Fig 3-7) and to 
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a lesser extent by the USPIO-NH2 (Fig3-6) and Poly-COOH (Fig 3-7). P-
selectin is shed rapidly from the cell surface so may not be as robust a 
marker of platelet activation as PMA which had a more consistent dose-
dependent response.  PAC-1 binding was increased by Poly-NH2, the top 
dose of USPIO-NH2 and the Poly-COOH however PAC-1 is a later marker of 
platelet activation and requires full ɑ-body de-granulation and requires potent 
activation.  
 
Platelet aggregometry was carried out in a 96-well plate Fig 3-12 shows a 
dose response to TRAP-6 demonstrating the technique is consistent, giving a 
characteristic platelet aggregation response. After 20 min only the Poly-NH2 
ENP caused significant increase in platelet aggregation (Fig 3-11). The 
aggregates can be seen in the wells indicated by red arrows in Fig 3-12.  
 
Platelet Hyper-reactivity 3.4.3 
 
The response of platelets to known agonist is an important test of their 
function. Any deviation from a normal response can manifest as a clinical 
condition. Here platelets that had been incubated with SPIO, USPIO-NH2 and 
USPIO-COOH showed increased sensitivity to agonists TRAP-6 and 
thrombin.  
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Platelets treated with ENPs showed a lower threshold for activation and 
increased sensitivity to TRAP-6 measured by surface p-selectin and PAC-1 
binding (Fig 3-13). This phenomenon was also demonstrated by measuring 
calcium influx in response to thrombin in platelets that had been pre-treated 
with ENP compared to saline treated platelets (Fig 3-14). Incubation with the 
nanoparticles alone (Fig 3-7, 3-9) showed some moderate increases in 
platelet activation but even nanoparticles that could not activate platelets 
showed here that they increased their sensitivity to agonists lowering their 
threshold of activation. 
 
MDMØ Inflammation 3.4.4 
 
MDMØ were incubated with SPIO, USPIO, USPIO-NH2 and USPIO-COOH 
for 24 and 72-hours. The ENP were tolerated well by the cells and displayed 
no cytotoxic effects (see Appendix I). The most prominent effect was seen 
after treatment with the USPIO-COOH which caused an up-regulation in 
ICAM-1 detected by flow cytometry and confocal microscopy, comparable to 
that of the potent inflammagen LPS (Fig 3-13). This coincided with increased 
release of IL-8 from the USPIO-COOH treated cells (Fig 3-16, Fig 3-17) 
which persisted over the 72-hour period. No effects were seen after 
treatment with the other ENP suggesting it may be a carboxylic specific 
effect. While no specific mechanism was studied to account for this unique 
carboxylic driven effect the TEMs suggested that the USPIO-COOH were 
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taken up more readily by the cells which resulted in higher intracellular 
concentrations of the particles (Fig3-15). TNF-ɑ, IL-1β, IL-6 and VCAM were 
measured by ELISA and flow cytometry respectively but were not 
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Platelet Activation 3.4.5 
 
Figure 3-3. Platelet-Monocyte Aggregates in whole blood after incubation 
with iron-oxide ENPs. The data suggest that surface charge may affect the 
extent to which ENP’s can activate platelets, positively charged,  aminated 











Figure 3-4 Platelet-Monocyte Aggregation in Whole blood in vitro after 
incubation with polystyrene beads. The data support the theory that positively 
charged ENP are more potent platelet activators than negatively charged 













Figure 3-5 Confocal microscopy of platelet monocyte nanoparticle 
aggregates. Platelet (green), monocyte (red), nanoparticle (blue) aggregates 
isolated from whole blood. The nanoparticles appear to bind to and activate 
platelets which then in-turn bind to circulating monocytes. Images are 
representative. 
 




Figure 3-6 Platelet-Neutrophil Aggregates in whole blood in vitro after 
incubation with iron-oxide nanoparticles. The data suggest that surface 
charge may affect the extent to which ENP’s can activate platelets, positively 
charged,  aminated particles being the most potent as they were with the 








Figure 3-7 Platelet-Neutrophil Aggregation in Whole blood in vitro after 
incubation with polystyrene beads. The data support the theory that positively 
charged ENP are more potent platelet activators than negatively charged 








Figure 3-8 Platelet Surface P-selectin Expression after incubation with iron-
oxide nanoparticles. P-selectin was significantly increased after incubation 
with USPIO-NH2 but not SPIO, USPIO, or USPIO-COOH. Data represent 








Figure 3-9 Platelet Surface P-selectin Expression after incubation with 
polystyrene beads. The Poly-NH2 beads were potent platelet activators 
increasing platelet surface p-selectin in a dose dependent manner. The Poly-
COOH beads had an effect at the highest dose. Data represent mean±SEM 








Figure 3-10 Binding of PAC-1 to platelet surface after incubation with iron-
oxide nanoparticles. Though PAC-1 binding was low (<5%) slight increases 








Figure 3-11 Binding of PAC-1 to platelet surface after incubation with 
polystyrene beads. A bigger increase in PAC-1 binding was seen with the 
beads again the aminated nanoparticles were more potent platelet activators. 









Figure 3-10 Platelet Aggregation in platelet rich plasma in response to the 










Figure 3-11 Platelet Aggregation in platelet rich plasma in response to ENPs. 
The positively charged aminated beads caused a dose dependent increase 
in platelet aggregation. Data represent mean±sem, n=5. 
 
Figure 3-12 Images of platelet aggregates in 96 well plate showing 
aggregates indicated by red arrows, after 20 minutes incubation with A) 
TRAP-6, B) Aminated beads, C) Saline, D) Carboxylated beads.  
 
 





Figure 3-13 Platelet Hyper-reactivity. Platelet surface p-selectin and PAC-1 
were significantly increased compared to the untreated control when co-
incubated with nanoparticles and 10µm TRAP-6 (denoted by #). Significant 
increases were also seen when comparing TRAP-6 alone to TRAP-6 
nanoparticle co-incubations (denoted by *). Data represent mean ± sem, n=5 













 Figure 3-14 Calcium influx. Platelets incubated with SPIO showed increased 
sensitivity to thrombin measured by calcium influx. The increases were 
significant when compared to platelets incubated with saline alone. Data 














Figure 3-15 ICAM-1 Expression in monocyte derived macrophage cells after 
treatment with iron-oxide nanoparticles after 24 and 72 hours. Treatment with 
the carboxylated iron-oxide nanoparticles caused an increase in ICAM-1 
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Figure 3-16 Confocal Microscopy ICAM-1 Expression at 24hrs. A dose 
dependent increase in ICAM-1 fluorescence can be seen (d(i), d(ii)) in the 



























Figure 3-17  IL-8 pg/mL at 24hrs in cell culture supernatants. Treatment with 
the carboxylated iron-oxide nanoparticles caused an increase in IL-8 in cell 
culture supernatants. This effect persisted over 72-hours and was specific to 








Figure 3-18.Transmission electron micrographs showing nanoparticle uptake 
in MDMØ cells (increasing magnification from left to right). Row a) SPIO, row 













In recent years considerable effort and creativity have been applied to the 
development and study of ENP surfaces with the aim of understanding and 
controlling their interactions with bio-macromolecules. From a chemist’s point 
of view, although challenging, most ENPs can be functionalised with a variety 
of ligands increasing their utility in clinical medicine;  however there are many 
aspects of particle functionalisation that need to be addressed in their 
translation from bench-to-bedside. Persuasive evidence exists in the 
literature that surface modification of non-metallic ENPs plays a role in 
platelet activation (McGuinnes, Duffin, Brown, Mills, Megson, MacNee, 
Johnston, Lu, Tran, Li, Wang, Newby, & Donaldson 2011).  
 
Here, it was demonstrated, in vitro, that the surface charge and 
functionalisation of ENPs can activate platelets and induce an inflammatory 
response in monocyte derived macrophages. 
 
 It was found that positively charges ENPs were more potent activators of 
platelets, inducing the formation of platelet-leukocyte binding, up-regulation 
of platelet surface p-selectin and PAC-1, and triggered platelet aggregation. 
As well as having effects directly on platelets all ENPs tested made platelets 
more sensitive to known agonists TRAP-6 and thrombin. The negatively 
charged carboxylated USPIO activated monocyte derived macrophage cells 
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causing them to release pro-inflammatory cytokine IL-8 and up-regulated 
ICAM-1 protein expression. 
 
  Recently it has been shown that the surface functionalisation of ENPs 
determines their behaviour in post-ischaemic tissue with amine modified 
ENPs causing enhanced microvascular permeability and it is hypothesised 
that the interaction of aminated ENPs with cell membranes could be 
mediated by electrostatic forces which have been previously reported for 
cationic molecules and negatively charged cell membranes (Rehberg et al. 
2010;Rehberg et al. 2012b).  
 
Platelet-monocyte aggregates are heterotypic complexes found circulating in 
the peripheral blood in response to platelet activation (Passacquale, 
Vamadevan, Pereira, Hamid, Corrigall, & Ferro 2011) and have been shown 
to be a more sensitive assessment of platelet activation than traditional 
measures of platelet activation like p-selectin, which is readily shed from their 
surfaces (Michelson et al. 1996). Interactions between monocytes and 
platelets are predominantly mediated by divalent cation-dependent 
interactions between platelet p-selectin and p-selectin glycoprotein ligand-1 
expressed on monocytes.  
 
Platelet-monocyte complexes have been shown to be important in 
inflammatory diseases such as atherosclerosis (Barnard et al. 
2003;Freedman and Loscalzo 2002). Here positively charged ENPs were 
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more potent activators of platelets than negatively charged ENPs. Positively 
charged ENPs significantly increased platelet surface p-selectin expression 
and the formation of platelet-monocyte aggregates. Given the relevance of 
circulating platelet-monocyte aggregates to cardiovascular disease and their 
correlation with patients with ACS (Freedman & Loscalzo 2002) platelet-
monocyte aggregation could be used as a quick standard method for 
screening ENPs intended for clinical use; identifying those which could have 
the potential to promote inflammation and exacerbate atherothrombotic 
disease (Passacquale, Vamadevan, Pereira, Hamid, Corrigall, & Ferro 2011).  
 
The response of platelets to the agonist TRAP-6 was measured after 
incubation with SPION, USPION-NH2 and USPION-COOH. In comparison 
with the negative control TRAP-6 did not cause a significant elevation in 
platelet activation. The same dose of TRAP-6 when added to platelets 
incubated with ENPs caused significant increases in both CD62P expression 
and Pac-1 binding showing that incubation with ENPs causes platelets to 
lower their threshold of activation or become hyper-reactive. Calcium 
mobilisation plays an important role in platelet activation and aggregation 
mediating cytoskeletal changes and secretion (Allison et al. 2006). Thrombin 
was used to induce calcium influx and increase intracellular calcium ion 
concentration in platelets. When this was repeated in platelets incubated with 
increasing doses of SPIO intracellular calcium was significantly increased in 
a dose dependent manner compared to saline treated platelets. Taken 
together these results suggest that surface functionalisation has a bearing on 
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platelet activation, the positively charged ENPs being more potent activators 
of platelets than negatively charged particles but it seems that exposure to 
ENPs in general caused platelets to become more responsive to external 
agonists or become hyper-reactive a condition known to contribute to 
atherothrombotic disease (Kubik and Richardson 1987). 
 
Intercellular adhesion molecule 1 (ICAM-1) is an important mediator of cell 
adhesion, immunostimulation and maintenance of the pro-inflammatory 
environment (Watanabe and Fan 1998). Adhesion molecules such as ICAM-
1 are involved in the initial stages of plaque progression involves the 
recruitment of inflammatory cells from the circulation and their 
transendothelial migration. The basic science of inflammation biology applied 
to atherosclerosis has afforded considerable new insight into the 
mechanisms underlying the recruitment of leukocytes. This process is 
predominantly mediated by cellular adhesion molecules, which are 
expressed on the vascular endothelium and on circulating leukocytes in 
response to several inflammatory stimuli. Two molecules mediating cell-cell 
adhesive interactions are ICAM-l and the integrin LFA-l (Brown et al. 1993). 
Persistent up-regulation of adhesion molecules could lead to chronic cell 
activation, inflammation, and propagation of disease. 
 
Carboxylated ENPs in this study caused significant increases in both ICAM-1 
and IL8 pg/mL, which persisted over a 72-hour period. These increases were 
only seen after treatment with the carboxylated ENPs suggesting it may be a 
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carboxyl-specific effect potentially driven by increased cellular recognition 
and uptake of carboxylated ENP as seen by transmission electron 
microscopy. It has previously been shown that exposure to occupational 
dusts and particles can cause up-regulation of macrophage ICAM-1 and 
cause aggregation of alveolar macrophages after pulmonary instillation into a 
rat model (Brown, Dransfield, Wetherill, & Donaldson 1993) and another 
study showed that exposure to iron-oxide ENPs caused up-regulation of 
ICAM-1 and Il-8 in endothelial cells (Zhu et al. 2011b). Up-regulation of 
ICAM-1 can lead to increased cell binding to vascular endothelium as well as 
homotypic macrophage binding maintaining and driving the inflammatory 
environment and potentially exacerbating plaque progression (Libby et al. 
2011).  
 
A number of limitations need to be taken into consideration when interpreting 
this data. As with all in vitro studies the conditions are artificial and do not 
adequately mimic the in vivo situation. This may be particularly important for 
platelets as they are heavily influenced by rheological conditions. Other cell 
types, such as endothelial cells, which play a central role in cardiovascular 
disease, may be affected by ENPs and further research is needed into ENP-
platelet-endothelial cell interactions. The ENP used in this study, though 
relevant to clinical use, do not reflect the scope of ENPs in development for 
intra-venous use. 
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The data in this study indicate that surface functionalisation plays a critical 
role in ENP toxicity. Not only that, but toxicity may be different across cell 
types. As seen here the positively charged aminated particles had a big 
effect on platelets in vitro while the negatively charged carboxylated USPIOs 
had a pro-inflammatory effect on monocyte derived macrophages. This study 
shows that relatively simple in vitro techniques could be used to determine 
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ENPs designed for medical use share certain properties with CDNPs and 
may exert similar pro-thrombotic effects. In this study a well validated model 
of thrombosis, the Badimon chamber, was used to investigate whether ENPs 
induce thrombosis in flowing blood subjected to then. As this was the first 
time the Badimon chamber was used for such a study its utility as an 
appropriate model was also under investigation. Flow cytometry was used to 
assess platelet activation and a cytometric bead array was used to detect 
inflammatory cytokines sampled from the chamber. 
 
In a randomised, double-blind, cross-over study Feraheme®, Poly-NH2 and 
Poly-COOH nanoparticles were added extracorporeally to native whole 
blood. The higher dose of Feraheme® (300µg/mL) caused significant 
(p=0.002) increase in thrombus formation under high shear but not low shear 
conditions. No platelet activation was detected compared to the saline 
control. The negatively charged Poly-COOH caused significant increases in 
platelet surface p-selectin, PAC-1, p<0.05 for all, but this did not translate 
into an increase in thrombus formation.  
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The Badimon chamber showed promise as a model for testing the effect of 
ENPs on thrombus formation and resolves some of the limitations of the in 
vitro toxicology studies.  





Platelet activation and thrombosis are critical determinants of the clinical 
outcome following atheromatous plaque rupture, which often results in 
thrombotic coronary artery occlusion, myocardial infarction and sudden 
cardiovascular death. A variety of ENPs are under development for imaging 
atherothrombotic vascular disease and for the delivery of targeted 
therapeutic ENPs to the unstable plaque.  
 
Using a carefully characterised exposure system, we have previously shown 
that exposure to combustion-derived ENPs in dilute diesel exhaust causes an 
impairment of vascular and fibrinolytic function (Mills et al. 2005), and 
induces asymptomatic myocardial ischemia in patients with coronary heart 
disease (Mills, Tornqvist, Gonzalez, Vink, Robinson, Soderberg, Boon, 
Donaldson, Sandstrom, Blomberg, & Newby 2007b). More recently we have 
demonstrated using a Badimon chamber that inhalation exposure to diesel 
exhaust increases platelet activation and thrombus formation in man 
(Lucking, Lundback, Mills, Faratian, Barath, Pourazar, Cassee, Donaldson, 
Boon, Badimon, Sandstrom, Blomberg, & Newby 2008). These pro-
thrombotic effects may well be mediated by a direct effect of circulating ENPs 
on platelet function. 
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  ENP contrast agents that specifically target unstable atheromatous plaques 
have the potential to assist in both the diagnosis and treatment of vascular 
lesions (Nahrendorf et al. 2009b). However, because they are delivered 
directly into the blood they also have to the potential to activate platelets and 
thus adversely affect clinical outcome (McGuinnes, Duffin, Brown, Mills, 
Megson, MacNee, Johnston, Lu, Tran, Li, Wang, Newby, & Donaldson 2011). 
As yet there are no published studies addressing whether the direct 
intravascular infusion of these ENP contrast agents exert adverse effects on 
platelet or vascular function. The ex-vivo evaluation of nanoparticulates, and 
test particles with differing physicochemical properties, will help to determine 
the characteristics of nanoparticulates that influence platelet function and 
thrombosis. These studies are an essential part of the development of safe 












 Nanoparticles and Atherosclerosis: Resolving the Paradox 
122 
 
Aims and Hypothesis 4.3 
 
We hypothesise that  medical ENPs designed for intravenous use could have 
similar pro-thrombotic effects as inhaled CDNPs due to the physical 
similarities they share such as size and surface area and that the Badimon 
chamber could be used as an ex-vivo model to assess the pro-thrombotic 
nature of ENPs designed for biomedical use, specifically those intended for 
intravenous injection. 
 
Our preliminary investigations suggest that ENM surface charge may be an 
important determinant in their thrombogenicity. Using the Badimon chamber 
as an ex-vivo we aimed to mimic more realistic conditions of thrombus 
formation and the potential for ENPs to influence this. 
 
The aim of this study is to investigate the effects of ENP contrast agents on 
platelet function and thrombogenesis ex vivo. ENPs designed for atheroma 
imaging were compared with ENPs of known activity in assays of platelet 









The Badimon Chamber 4.4.1 
 
The Badimon chamber is an ex vivo model of deep arterial injury and 
thrombus formation used previously to study the effects of diesel exhaust 
ENP inhalation on thrombosis in man (Lucking, Lundback, Mills, Faratian, 
Barath, Pourazar, Cassee, Donaldson, Boon, Badimon, Sandstrom, 
Blomberg, & Newby 2008;Lundback, Mills, Lucking, Barath, Donaldson, 
Newby, Sandstrom, & Blomberg 2009).  The chamber permits an 
assessment of thrombus formation in whole blood without the need for anti-
coagulants or exposure of the patient to the compounds being tested. While 
principally used to assess the impact of novel antithrombotic agents it can be 
readily modified to assess the effects of ENM on thrombosis by adding them 
into the extracorporeal blood flow at a defined concentration and assessing 
the impact on thrombosis compared to untreated blood. A pump is used to 
draw blood from the ante-cubital vein through the chambers, maintained at 
37°C in a water bath. The rheological conditions in the first chamber simulate 
those of patent coronary arteries (low-shear rate), whereas those in the 
second and third chambers simulate those of stenosed coronary artery (high-
shear rate) (Lucking, Lundback, Mills, Faratian, Barath, Pourazar, Cassee, 
Donaldson, Boon, Badimon, Sandstrom, Blomberg, & Newby 2008). The 
thrombus formed in the low shear chamber is fibrin and macrophage- rich 
whereas the thrombus formed in high shear conditions is platelet- rich 
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(Lucking, Lundback, Mills, Faratian, Barath, Pourazar, Cassee, Donaldson, 
Boon, Badimon, Sandstrom, Blomberg, & Newby 2008). This powerful 
technique permits the dynamic formation of thrombus to be observed and 
allows the assessment of thrombotic and anti-thrombotic interventions. The 
chamber is therefore potentially able to assess ENP interactions with specific 
blood cells and types of thrombus.  
The Badimon chamber was custom made at Edinburgh University based on 
an original Badimon chambers obtained from the designer of the chamber. 
The chamber themselves are Plexiglas blocks through which a cylindrical 
hole has been bored. This mimics the typical cylindrical shape of vasculature. 
The bore size is either 0.2 or 0.1 cm diameter modelling low and high shear 
stress respectively. Portions of these channels are left open in order to 
expose the flowing blood to a biological or prosthetic surface. Another 
Plexiglas block is placed on top of this block, on top of the non-exposed side 
















Figure 4-1 Badimon Chamber Set-up 
 
 Schematic of Badimon chamber set-up showing from left to right the flow of 
blood from the patient through the tubing where the blood mixes with the 
extra-corporeal drug, in this case particles, then across the three chambers 
lined with denuded porcine aorta and on to the effluent container. 
 
Table 4-1 Flow characteristics of perfusion chambers 
Tubular diameter (cm) Blood flow rate 
(mL/min) 






















 (Badimon et al. 2012) 
Porcine Aorta Lined Chambers 






Figure 4-2  Badimon chamber set-up with volunteer 
 
Images of Badimon chamber in action showing blood flowing from the subject 








Figure 4-3 Preparation of Porcine Aortic Strips  
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Images showing the steps in the preparation of the porcine aortic strips for 
use in the Badimon chamber. Image A shows the whole untouched aorta as 
supplied by the company (Pel-Freez® Biologicals). The aorta is first trimmed 
of its excess fat and the remainder of the aortic arch is removes (B). The 
aorta is cut along the branches (C) and then cut into sections lengthways so 
as to fit in the chamber (D).  The edges of the sections are squared off and 
cut into strips using a template (E). The top corner of the strip is marked to 
show from which end the strip was denuded. Strips are denuded from thick 
end to thin by making a small incision in the top corner and then gently 
peeling back the endothelial layer and a small amount of the underlying 
intimal layer (F). The layer of tissue that’s removed should be as thin as 
possible and come away in one piece (G). It is important to go over the 
surface of the strip with forceps ensuring there are no loose flaps of tissue, 














Figure 4-4 Quantification of Thrombus Area 
 
Thrombus is formed along the entire length of the exposed substrate (equal 
to the window of the flow channel [2 cm]). Images were acquired at X20 
magnification, and the thrombus area was measured using an Ariol image 
acquisition system (Applied Imaging, USA) by a blinded operator. Results 
from at least six sections were averaged to determine thrombus area for 
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Study Design 4.4.2 
 
 Healthy volunteers (n=12) attended the clinical research facility at the 
Edinburgh Royal Infirmary on two occasions for a series of Badimon chamber 
perfusion studies. A 27-guage intravenous cannula was placed in a large 
antecubital fossa vein. A peristaltic pump drew blood from the antecubital 
vein through a series of perfusion chambers maintained at 37˚C in a water 
bath as described above. During the first visit saline (control) or suspensions 
of ENPs were infused to achieve local concentrations of 0.15 mg/mL and 
0.3mg/mL in the extracorporeal circuit of the Badimon Chamber. The order of 
extra-corporeal infusions was randomized using a balanced block design. All 
studies were performed in a temperature controlled clinical research facility 
by staff blinded to exposure allocation.  
 
The primary end point was thrombus area (high and low shear conditions) 
with secondary endpoints including platelet-monocyte aggregation, plasma 
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Nanoparticle Panel 4.4.3 
 
4.4.3.1 Feraheme®  
 
Feraheme® was prepared at the following concentrations: diluted 1:10 (3 
mg/mL) or diluted 1:20 (1.5mg/mL) in sterile isotonic saline (0.9%) and bath 
sonicated for 5 min prior to perfusion. Feraheme® solutions were infused at a 
rate of 1mL/min in the extra-corporeal circuit and mixed with 50 mL of blood 
drawn through the perfusion chamber at 10 mL per minute over 5 mins 
reaching a final concentration of 150µg/mL or 300µg/mL in blood. 
 
4.4.3.2 Model Engineered Nanoparticles 
 
Carboxylated and aminated ENPs (50nm) (Polysciences Inc., Sigma-
Aldrich®, respectively) were supplied at 25 mg/mL and diluted 1:8.3 in sterile 
isotonic saline (0.9%) to achieve a stock solution at 3 mg/mL and bath 
sonicated for 5 min prior to perfusion. ENP solution was infused at a rate of 
1mL/min into the extra-corporeal circuit and mixed with 50 mL of blood drawn 
through the perfusion chamber at 10 mL per minute over 5 mins reaching a 
final concentration of 0.3mg/mL in the extracorporeal circuit. 
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Visit 1 4.4.4 
 
During visit one; subjects underwent three Badimon chamber perfusion 
studies in a randomised order with the addition of either normal saline or 
Feraheme® USPION at a final concentration of 0.15 mg/mL or 0.3 mg/mL. 
0.15 mg/mL is based on the concentration of USPION found in the systemic 
circulation following intravenous infusion of 4mg/kg USPION in previous 
clinical trials 20 minutes after infusion (Landry et al. 2005). The ex-vivo study 
included two concentrations of USPION; 0.15 mg/mL to reflect 
concentrations delivered during a continuous infusion over 30 mins of 4mg/kg 
USPION, and as the purpose of the study is to determine the safety of the 
USPIONs we included a dose two fold higher than a patient would ever be 
exposed to in a clinical situation. 
 
Visit 2 4.4.5 
 
During visit two, subjects underwent three Badimon chamber perfusion 
studies in a randomised order with the addition of either normal saline or 
positively charged aminated latex beads or negatively charged carboxylated 
latex beads at a final concentration of 0.3 mg/mL. These charged model 
ENPs have been shown to consistently cause platelet aggregation and 
platelet-monocyte binding at this concentration (McGuinnes, Duffin, Brown, 
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Twelve healthy, non-smoking subjects, age 18-65 year old were identified 
from the healthy volunteer database. Subjects with previous medical history 
or on regular medication including the oral contraceptive pill and non-
steroidal anti-inflammatory agents with anti-platelet activity were excluded. All 
subjects underwent a general examination including height, weight, heart 
rate, and blood pressure. To exclude subclinical haematological, renal or 
hepatic disease routine haematological (full blood count) and clinical 
chemistry (urea and electrolytes, liver function,) tests were measured prior to 
enrolment. 
 
Inflammatory Measures 4.4.7 
 
Effluent was collected from the chamber and analysed for plasma IL-1ß, IL-
12p70, IL-10, IL-6, IL-8 and TNF-αusing a BD™ human inflammatory 
cytometric bead array (BD Biosciences).  
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Platelet Activation 4.4.8 
 
Effluent was also analysed for platelet-monocyte aggregation and platelet 




Iron content by inductively coupled plasma mass spectrometry (ICPMS). 
Whole blood Iron content was measured by inductively coupled plasma mass 
spectrometry (ICPMS) in effluent from the Badimon chamber to ensure the 
addition system is working as expected. 
 
Blood was also collected from healthy volunteers taking part in a separate 
study (11/MRE00/5) in which healthy volunteers were directly infused with 





Statistical analysis of data will be performed using GraphPad Prism. Primary 
and secondary end-points following each infusion will be compared with 
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saline control with data analysed using repeated measures 1-way analysis of 
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Subjects recruited were considered healthy volunteers, average age 38±3, all 
subjects were male and did not differ significantly with respect to gender, 
age, height, and weight (Table 4-1) all subjects attended for two studies and 
reported no adverse effects having taken part.  
 
Inflammatory Markers 4.6.2 
 
There was a heterogeneous response in inflammatory cytokines in serum 
sampled from the chamber with the addition of either Feraheme® (Table 4-




Iron concentration in Badimon effluent correlated well with the estimated 
addition (Table 4-3). The net iron value for the lower dose was 116.91±12.55 
µg/mL and the higher dose was 240.75±8.83 µg/mL. The higher dose was 
roughly double the lower dose as expected and closely matched the Cmax 
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previously reported in the literature, 126.0±32.6 µg/mL, (Landry, Jacobs, 
Davis, Shenouda, & Bolton 2005). To validate the calculated extracorporeal 
doses used blood was collected from healthy volunteers taking part in a 
separate MRI study that were receiving Feraheme®. Blood was sampled at 
baseline pre-Feraheme®, and 24-hours post Feraheme®. The in vivo iron 
concentrations correlated well with the estimated concentrations, 71.56±11.5 
µg/mL 24-hours post.    
 
Platelet Activation 4.6.4 
 
There were no significant increases in platelet-monocyte aggregates, platelet 
surface p-selectin, PAC-1 or CD36 following the addition of the lower or 
higher doses of Feraheme® when compared to the saline control.  
 
The Poly-COOH beads increased platelet surface p-selectin (p=0.003), CD36 
(p=0.002) and PAC-1 (0.0003) whereas the Poly-NH2 had no such effects 
compared to saline control. Neither of the charged beads significantly 
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Thrombus Formation 4.6.5 
 
Thrombus formation in the high-shear chamber increased following addition 
of both doses of Feraheme® though the lower dose did not reach 
significance whereas the higher dose did (p=0.002). No increase in thrombus 
was seen in the low-shear chamber. Surprisingly the addition of Poly-NH2 
and Poly-COOH caused a significant decrease in thrombus formation 
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Table 4-2 Baseline Characteristics of Healthy Volunteers. Data represent 


















Height (m) 1.75±0.02 
Body mass index (kg/m2) 26±0.9 
Heart rate 65±3 
Systolic blood pressure 
(mmHg) 
134±3 
Diastolic blood pressure 
(mmHg)  
81±3 
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Table 4-3 Inductively Coupled Plasma Mass Spectrometry from 
extracorporeal study. Data represent mean ± SEM n=12  
 
Extracorporeal Drug Total Iron Concentration in 
Effluent (mg/L) 
Saline 418.67±8.14 
Feraheme® 150µg/mL 535.58±12.56 
Feraheme® 300µg/mL 659.42±8.83 
 
 
Table 4-4 Inductively Coupled Plasma Mass Spectrometry from healthy 




Total Iron concentration in whole 
blood from healthy volunteers 
(mg/L) 
Pre-Feraheme® 467.94±19.1  
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Table 4-5 Inflammatory cytokine levels after the addition of Feraheme® to the 








IL-12p70  0±0  2.8 ±1.8  2.3±2.2  
TNF-α  9.5±2.3  10.9±2.6  10.2±2.5  
IL-10  0±0  0.5±0.5  0±0  
IL-6  1.3±0.8  1.3±0.8 0.9±0.6  
IL-1β  6.2±1.3  5.4±1.3  5.6±1.2  
IL-8  4.5±1.3  3.4±1.2  3.3±0.9  
 
Table 4-6 Inflammatory cytokine levels after the addition of Polystyrene 
beads to the extracorporeal circuit. Data represent mean ± SEM n=12 
Cytokine 
(pg/mL)  
Saline  Positive bead Negative bead 
IL-12p70  0±0  4.3±2.8 7.3±3.2 
TNF-α  9.5±2.3  12.5±2.9 14.5±2.8 
IL-10  0±0  1.9±1.0 2.6±1.0 
IL-6  1.3±0.8  1.7±0.9 0.9±0.6 
IL-1β  6.2±1.3  9.3±1.5 7.5±1.2 
IL-8  4.5±1.3  7.1±1.0 6.8±1.3 
 




Figure 4-5 Platelet activation markers measured in whole blood sampled from 
the Badimon chamber after the addition of Feraheme®. No increase in 
platelet activation was seen for either dose of Feraheme®. Parameter 
assessed included platelet monocyte aggregation, platelet surface p-selectin, 
PAC-1 and CD36. Data represent mean±sem, n=11-12. 
 




Figure 4-5 Thrombus formation under low shear with the addition of 
Feraheme®. No increase in thrombus was seen for either concentration of 









Figure 4-6. Thrombus formation under high shear with the addition of 
Feraheme®. While no increase in thrombus area was seen with the lower 
dose of Feraheme® a significant (p=0.002) increase in thrombus was seen 















Figure 4-6. Platelet activation markers measured in whole blood sampled 
from the Badimon chamber after the addition of positively or negatively 
charged beads. An increase in markers of platelet activation could not be 
detected after the addition of aminated beads however the carboxylated 
beads resulted in increases in platelet p-selectin, PAC-1 and CD36. Data 








Figure 4-10 Thrombus formation under low shear with the addition of 
positively or negatively charged polystyrene beads. The low shear chamber 
is predominantly characterised by macrophage rich thrombus which was not 












Figure 4-11 Thrombus formation under high shear with the addition of 
positively or negatively charged latex beads. No increase in thrombus are 
was observed despite the beads known ability to activate platelets in 
















The process of thrombosis is heavily influenced by the local rheological 
conditions and endothelial integrity. The Badimon chamber has many 
advantages over other models of thrombosis. It is designed to retain the 
cylindrical shape typical of vasculature; and is capable of simulating a broad 
range of flow conditions through altering the flow rate into the chamber as 
well as allowing both laminar and nonparallel streamline flows. The chamber 
allows for the addition of a variety of substances, extracorporeally, assessing 
their effect on thrombus formation in native whole blood. No studies have 
been carried out to determine the potential for intravenous medical ENPs to 
exacerbate atherothrombotic disease despite their similarities to CDNPs, now 
shown to be the most likely mediator of the adverse health effects of air 
pollution, (Mills, Miller, Lucking, Beveridge, Flint, Boere, Fokkens, Boon, 
Sandstrom, Blomberg, Duffin, Donaldson, Hadoke, Cassee, & Newby 2011) 
(Donaldson 2006).  
 
In this study we hypothesised that the Badimon chamber could be used as 
an ex-vivo model to assess the pro-thrombotic nature of ENPs designed for 
clinical use, specifically those intended for intravenous injection. Twelve 
healthy volunteers were recruited and attended the clinical research facility 
on two separate occasions. On each visit three runs of the Badimon 
chamber, lasting 5 minutes each, were carried out; 1 saline control run and 2 
runs where ENPs were added to the blood before it entered the chamber.  
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Two separate studies were carried out the first was to determine whether an 
FDA approved USPION Feraheme® could increase thrombus formation in 
the Badimon chamber at the physiologically relevant dose of 150µg/mL 
(Landry, Jacobs, Davis, Shenouda, & Bolton 2005) and as the purpose of the 
study was to determine the safety profile of the USPIONs we included a dose 
two fold higher than the final serum concentration but theoretically a dose 
that could be reached locally at some sites during administration of the bolus 
(300µg/mL). The second study was to determine a potential mechanism 
behind the impact of ENPs on thrombus formation. We did this with 
manufactured latex beads of known size and surface functionalisation.  
 
This study demonstrates that the Badimon chamber could be a useful model 
to test the thrombogenicity of ENPs designed for medical use. Thrombus was 
significantly increased under high shear with stress the addition of the higher 
dose of Feraheme®. However with the charged ENPs, which activated 
platelets in vitro and ex vivo, significantly reduced thrombus in the high shear 
chamber. No increases in inflammatory markers were detected compared to 
saline control. In order to verify whether or not the addition system was 
working efficiently whole blood was sampled from the chamber during each 
USPION/saline run then analysed for iron content using ICPMS. The results 
indicated an increase in blood iron content consistent with the addition of 
both the lower and higher dose of Feraheme®. Thus we could be confident 
that the ENPs were mixing with the blood thoroughly and we were delivering 
our theorised doses with very little being lost on tubing or in the chambers.  
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A range of inflammatory cytokines (IL-1ß, IL-12p70, IL-10, IL-6, IL-8 and 
TNF-α) were analysed in serum sampled from the chamber effluent both 
before and after addition of the ENPs. There were no increase in the 
cytokines tested but that is not altogether surprising given the very short (5 
minutes) time frame over which the experiment took place. Even some of the 
most potent inducers of cytokine production e.g. lipopolysaccharide (LPS) 
can take up to 20 minutes to stimulate measurable increases in TNF-α 
production from monocyte/macrophage cells (Lacy and Stow 2011).  
 
We observed an increase in thrombus formation in the high shear chambers 
after the addition of Feraheme® at both at both the lower and higher dose 
the latter reaching significance. No increases in thrombus were seen in the 
low shear chamber suggesting any increases seen are most likely due to 
platelet activation (Lucking, Lundback, Mills, Faratian, Barath, Pourazar, 
Cassee, Donaldson, Boon, Badimon, Sandstrom, Blomberg, & Newby 2008).  
 
Platelet–monocyte binding is principally dependent on p-selectin but, despite 
the increase in platelet rich thrombus in the high shear chamber, we did not 
observe an increase in the platelet surface expression of p-selectin or 
platelet-monocyte aggregation with either the low or high dose of 
Feraheme®. There was no increase in platelet surface activated 
gpIIßIIIα (PAC-1) or platelet surface CD36, which plays a role binding 
thrombospondin-1 and oxidised LDL cholesterol (Nergiz-Unal et al. 2011). 
Given the very short amount of time the platelets have to interact with 
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Feraheme® it is not surprising that there is not widespread platelet activation 
but rather localised increased thrombus formation in the presence of the 
extra stimulus of the denuded porcine aorta, suggesting the platelets may be 
more prone to activation after exposure to the Feraheme® but not directly 
activated by it.  Thrombus formation under flow is a tightly controlled process 
that takes place in the microenvironment around the vascular wall and plays 
a role in normal and pathological haemostasis and thrombosis. It is therefore 
not wholly surprising that there was not an overall increase in platelet 
activation in chamber effluent. 
 
Charged latex particles were used in the study as we thought they would be 
good candidates as a positive control for thrombus formation in the chamber 
as they caused significant platelet activation and aggregation in in vitro 
(Chapter 3) (McGuinnes, Duffin, Brown, Mills, Megson, MacNee, Johnston, 
Lu, Tran, Li, Wang, Newby, & Donaldson 2011). The negatively charged 
carboxylated beads caused significant increases in platelet activation (CD62-
p, Pac-1, CD36), however this did not translate to an increase in thrombus 
formation in either the low or high shear chambers. In fact in the high shear 
chamber there was a significant decrease in thrombus formation with the 
infusion of both beads. This could be due to the platelets being activated 
upon contact with the beads before entering the chamber and passing 
straight through and so no longer prone to further activation by the collagen 
surface within the chamber resulting in a false reduction in thrombus 
formation. This is an important factor to take into consideration when using 
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the chamber; taken at face value the data could be wrongly interpreted as 
showing that the charged latex beads reduced thrombus formation within the 
chamber. Any future studies using the Badimon chamber with charged 
particles should consider using a lower dose of the charged particles. 
 
As a model for testing the pro-thrombotic nature of ENPs the Badimon 
chamber is a promising technique but does have a number of limitations. 
This study used only one type of clinical nanoparticle; future studies would 
need to use a range of ENPs with of varying sizes, compositions and surface 
functionalisations to further validate it as a suitable technique to determine its 
usefulness as an ex-vivo model for testing the thrombogenicity of ENPs. The 
very short time the ENPs have to interact with the blood is another limitation 
of the technique; currently in this model the ENPs mix for a matter of seconds 
before it enters the chamber and does not fully reflect in in vivo situation 
where these ENPs have been shown to have a blood half-life of 9.3 to 14.5 h 
(Landry, Jacobs, Davis, Shenouda, & Bolton 2005) so has much more time to 
interact with platelets and other cells of the circulatory system. 
 
This study showed that an FDA approved drug designed for iron-replacement 
therapy, but also under investigation as a nanoparticulate contrast agent, can 
increase thrombus formation in an ex vivo model of thrombus formation in 
healthy volunteers. While the Badimon technique needs further validation the 
study highlights the need for more thorough testing of ENP- based drugs for 
intravenous administration to ensure the full range of their potential side 
 Nanoparticles and Atherosclerosis: Resolving the Paradox 
153 
 
effects and possible clinical consequences are known before being used in 
patients. ENPs are dealt with by the body differently from traditional drugs 
and are often retained in the body for a prolonged period of time. Particular 
care and attention should be paid to ENPs designed to interact with certain 
cells or those designed for prolonged retention in the circulatory system. 
Ultimately this study demonstrates that ENPs have unique toxicity profiles 
often not accommodated by traditional toxicity testing. To ensure the 
continued and safe use of this technology, more thorough testing of ENPs 
designed for medical used should be undertaken at the development stages 
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This study was designed to determine whether intra-venous Feraheme® 
increases thrombus in patients with cardiovascular disease.  
 
Patients with abdominal aortic aneurysms were recruited for a larger study 
monitoring disease progression with USPIO Feraheme® and MRI scanning. 
Thrombus formation, coagulation, platelet activation, and inflammatory 
markers were measured in a cohort of 8 patients both before and 1-hour after 
administering the Feraheme®. Thrombus formation was measured using the 
Badimon ex vivo perfusion chamber. Platelet activation was assessed by flow 
cytometry.  
 
Compared with baseline, Feraheme® infusion increased thrombus formation 
under high-shear conditions (p=0.03), and caused platelet activation with 
increased p-selectin (p=0.02) and CD36 (p=0.02). No increase in thrombus 
under low shear conditions was observed. 
 
Here it is shown for the first time that ENPs delivered directly into the blood 
may also have adverse prothrombotic effects in patients with cardiovascular 
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disease the clinical consequences of these findings are unknown but warrant 
further investigation. 
  




Abdominal Aortic Aneurysms 5.2.1 
 
Abdominal aortic aneurysms (AAA) frequently occur in patients with 
atherosclerosis and the two disease processes share several common risk 
factors. The formation, growth and rupture of aneurysm is now recognised to 
be the result of a complex interplay between biological and biomechanical 
factors (Weintraub 2009). 
 
Aneurysm tissue is abdominal aorta that is surgically removed and is 
characterised by excessive medial neovascularisation, infiltration of 
inflammatory cells (principally macrophages and B-lymphocytes) and 
irreversible remodelling of the extracellular matrix. These pathological 
processes do not affect the aorta uniformly but are focal in nature. Shear wall 
stress varies spatially within the aneurysm and tensile strength varies in 
different parts of the aneurysm sac. Focal neovascularisation is present at 
the site of rupture only and its presence corresponds to the degree of 
inflammation. These biological ‘hotspots’ represent sites of potential rupture 
and are potential targets of developing imaging strategies to assess the 
aneurysmal expansion rates and the risk of rupture (Michel et al. 
2011;Nchimi et al. 2010) 
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Patients with asymptomatic AAA are observed in a surveillance programme 
involving serial ultrasound measurements of the antero-posterior diameter of 
the aneurysm. The threshold at which intervention is considered for 
asymptomatic aneurysms is generally 55 mm reference. Whilst the risk of 
rupture increases with diameter reference, the absolute diameter of the 
aneurysm is not the sole determinant of the risk of rupture reference and up 
to a fifth of ruptured AAA are <55 mm in diameter reference, reference. MRI 
is emerging as a useful investigation for cardiovascular disease offering high-
resolution images without exposure to ionising radiation. In atherosclerotic 
disease, MRI can distinguish different plaque components including the 
fibrous cap, the lipid core and areas of calcification (van et al. 2011).  
 
In recent years, advances in magnetic resonance (MR) scanning have led to 
the development of novel nanoparticulate contrast agents to enhance 
cardiovascular imaging (Amirbekian, Lipinski, Briley-Saebo, Amirbekian, 
Aguinaldo, Weinreb, Vucic, Frias, Hyafil, Mani, Fisher, & Fayad 2007a). 
Ultra-small paramagnetic iron oxide (USPIO) ENPs can be taken up by 
macrophage in atheroma and detected by MRI imaging in animal models of 
disease (Sigovan, Boussel, Sulaiman, Sappey-Marinier, Alsaid, sbleds-
Mansard, Ibarrola, Gamondes, Corot, Lancelot, Raynaud, Vives, Lacledere, 
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Hypothesis and Aims 5.3 
 
A variety of ENPs are under development for imaging AAA and for the 
delivery of targeted therapies to the unstable plaque (Yilmaz, Rosch, Klingel, 
Kandolf, Helluy, Hiller, Jakob, & Sechtem 2011a). As yet there are no 
published studies addressing whether the direct intravascular infusion of 
these ENP contrast agents exert adverse effects on platelet or vascular 
function in patients with underlying cardiovascular disease. 
 
I have previously demonstrated that ENPs increase thrombus and platelet 
activation ex vivo in healthy volunteers therefore: 
 
 I hypothesise that ENPs, when delivered systemically will activate platelets 
and exert a pro-thrombotic effect in susceptible with atherothrombotic 














Study Design 5.4.1 
 
The study was performed with the approval of local research Ethics 
Committees, in accordance with the Declaration of Helsinki and the written 
informed consent of all participants. The study was performed with the 
approval of local research Ethics Committees, in accordance with the 
Declaration of Helsinki [REC 05/S1104/26].  
 
Nanoparticle Panel 5.4.2 
 
Feraheme® was supplied by Advanced Magnetics, Inc., Cambridge, MA. As 
supplied, each vial contains 510 mg of elemental iron in 17 mL (30 mg/mL). It 
was administered via a peripheral venous cannula at a dose of 4 mgFe/kg 
body weight at a rate of up to 1 mL/sec. This dose had been safely 
administered before and equates to 8% of total body iron for males and 9.5% 
for females, or about the same amount of iron as is contained in 1-2 units of 
blood.  
 
Subjects underwent MRI of the AAA before and 24-36 hours after 
administration of USPION; Feraheme®. Administration was performed by a 
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member of the research team or a qualified research nurse, in the Clinical 
Research Facility at the Royal Infirmary of Edinburgh. Non-invasive 
physiological monitoring (continuous ECG monitoring, oxygen saturation 
probe, non-invasive blood pressure, and temperature and nurse observation) 
was performed during Feraheme® administration.  
 Inclusion criteria  5.4.3 
 
Patients with an AAA >40 mm on ultrasound scanning.  
 
Exclusion criteria  5.4.4 
  
Any medical history or clinically relevant abnormality identified on the 
screening medical examination, vital sign measurement, or clinical laboratory 
examination. 
Subjects with planned AAA surgery. 
 
 Renal impairment with eGFR of <30 mls/min at screening, history of 
kidney transplant or history of contrast nephropathy. 
 Women of childbearing potential without contraception collagen-
vascular disease. 
 Inability to undergo magnetic resonance or computed tomography 
scanning.  
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Contraindication to MRI scanning (as assessed by local MRI safety 
questionnaire) which includes but not limited to: 
 Intracranial aneurysm clips (except Sugita) or other metallic objects, 
 History of intra- orbital metal fragments that have not been removed, 
Pacemakers, implantable cardiac defibrillators and non-MR 
compatible heart valves, 
 Inner ear implants, 




Venous blood was drawn at screening and/or during the study to measure 
biochemical markers of inflammation using a BD™ human inflammatory 
cytometric bead array (BD Biosciences).  
 
Platelet Activation 5.6 
 
Effluent from the chamber was analysed for platelet-monocyte aggregation 
and platelet activation by flow cytometry including p-selectin, PAC-1 binding 
and platelet surface CD36. 
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Badimon Study 5.7 
 
AAA patients (n=8) attended on one occasion for a series of Badimon 
chamber perfusion studies before and after USPION infusion. A 27-guage 
intravenous cannula was placed in a large antecubital fossa vein. A peristaltic 
pump drew blood from the antecubital vein through a series of perfusion 
chambers maintained at 37˚C in a water bath as described in detail in 






Statistical analysis of data was performed using GraphPad Prism. Primary 
and secondary end-points following each infusion will be compared with 
saline control with data analysed using paired student’s t-test. Statistical 












Patients were recruited as part of an on-going imaging study [REC 
05/S1104/26]. All 8 patients returned for the two visits and reported no 




There were no increases in inflammatory markers 1-hour post Feraheme® 
administration compared to saline control (Table 5-2). 
 
Platelet Activation 5.9.2 
 
Neither platelet-monocyte aggregation nor PAC-1 was increased 1-hour post-
Feraheme®. P-selectin, and CD36 however were increased 1-hour post 
Feraheme® compared to the baseline levels p=0.02 for both indicating 
systemic platelet activation most likely as a result of the direct administration 
of Feraheme. The effect of MRI on platelet activation was considered but 
discounted as there is no literature to date to suggest a magnetic field has 
any effect on platelet activation (Sagdiyev, 2012 ). 
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Thrombus Formation 5.9.3 
 
Thrombus formation was increased 1-hour post Feraheme® in the high-shear 
chamber compared with the baseline pre-Feraheme® values, p=0.03. No 
such increase were seen in the low-shear chambers suggesting this is a 
platelet driven effect which correlates well with the increase in platelet 
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Table 5-1 Baseline characteristics of AAA patients which participated in the 





Systolic Pressure 148±5 
Diastolic Pressure 80±3 
 
 
Table 5-2 Inflammatory cytokine detection using cytometric bead array pre- 
and 1-hour post- Feraheme® administration in AAA patients. Data represent 
Data represent mean ± SEM n=8 
 Before 
Administration  
1hr + administration  
IL-12p70  2.2±0.7  1.9±0.6  
TNF-α  11.1±0.9  15.25±0.9  
IL-10  -  -  
IL-6  1.6±0.3  1.3±0.3  
IL-1ß  9.95±0.4  7.75±0.7  
IL-8  9.35±0.6  8.4±0.5  
 





Figure 5-1 Platelet surface p-selectin expression in whole blood sampled 
from the Badimon chamber pre- and 1-hour post- Feraheme®. Data 









Figure 5-2 Platelet surface CD36 expression in whole blood sampled from 
the Badimon chamber pre- and 1-hour post- Feraheme® Data represent 









Figure 5-3 Thrombus formation under low shear pre- and 1-hour post- 









Figure 5-4 Thrombus formation under high shear pre- and 1-hour post- 

















Recently a novel class of MRI contrast agents containing SPIONs have been 
developed which provide additional biological and functional information 
through the detection of cellular inflammation within tissues. Ultrasmall SPIO 
(USPIO), with particle sizes in the range 10-30 nm, escape immediate 
recognition by the RES and persist in the bloodstream allowing them to be 
used to assess the accumulation of macrophages within vascular and 
lymphatic tissues (Richards, Semple, Macgillivray, Gray, Langrish, Williams, 
Dweck, Wallace, McKillop, Chalmers, Garden, & Newby 2011).  
 
Developing a reproducible in vivo model of thrombosis for use in human 
studies is challenging. The Badimon chamber is a validated ex vivo model of 
arterial injury and thrombosis (Badimon et al. 1999). It has previously been 
used to evaluate the effects of novel antithrombotic regimes (Osende et al. 
2001) and exposure to CDNPs (Lucking, Lundback, Mills, Faratian, Barath, 
Pourazar, Cassee, Donaldson, Boon, Badimon, Sandstrom, Blomberg, & 
Newby 2008) on thrombosis and has a number of advantages over other 
techniques.  
 
This is the first in man study to demonstrate that intra-venous infusion of 
ENPs can cause up-regulation of surface markers of platelet activation 1-
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hour post infusion and increased the thrombogenicity of blood in an ex vivo 
model of thrombus formation; the Badimon chamber.   
 
The Badimon chamber has previously been used as an ex vivo model of 
arterial injury and thrombosis after exposure to inhaled dilute diesel exhaust. 
Here we employed the model to assess the effect of intra-vascular ENPs on 
thrombosis. Thrombus area was significantly increased under high-shear 1-
hour post infusion of Feraheme®. Not only does this correlate well with the 
high-shear thrombus formation following extra-corporeal addition of 
Feraheme® to the chamber (Chapter 4) it goes some way to validating the 
model as a good candidate to take forward to look at new intra-vascular ENP 
formulations and contrast agents on thrombus formation in man.  
 
The flow cytometric data showed significant increases in platelet surface p-
selectin and CD36, 1-hour post infusion, both markers of activation. This 
correlates well with the increase in platelet-rich thrombus area in the high-
shear chamber. The increased time the Feraheme® had to interact with 
platelets in this study (1-hour) compared to the extracorporeal addition 
(<30sec) is the most likely explanation for the differences in significance. No 
increase in platelet-monocyte aggregates or inflammatory markers could be 
detected 1-hour post infusion.   
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Previous studies have successfully used the Badimon chamber to investigate 
the effects of smoking, blood glucose, platelet function, anti-platelet therapy, 
and exposure to diesel exhaust on thrombosis (Lucking, Lundback, Mills, 
Faratian, Barath, Pourazar, Cassee, Donaldson, Boon, Badimon, Sandstrom, 
Blomberg, & Newby 2008)(Badimon, Lettino, Toschi, Fuster, Berrozpe, 
Chesebro, & Badimon 1999)(Sambola et al. 2003). The results of this study 
correlate well with previous Badimon studies in susceptible patients. These 
susceptible populations have increased risk of acute cardiovascular events it 
is plausible that the effects seen in this study could translate into clinical 
events when these agents are used more widely.  
 
If the Badimon chamber is to be developed as a tool to model the pro-
thrombotic nature of intra-vascular ENP formulations future studies should 
include longer time-points. The results from this study are promising, 
demonstrating increased platelet-driven thrombus formation in combination 
with systemic platelet activation in man but only one relatively short time-
point was assessed.  The effects seen here could be transient and whether 
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 Final Comments Chapter 6 
Summary  6.1 
 
ENM are likely to have a big impact on diagnostic assays, medical imaging, 
and targeted therapeutics in the near future. Characteristics of these ENPs, 
such as size, surface area, charge and surface chemistry as well as the 
method by which they are delivered will determine their distribution, efficacy 
and potential toxicity. ENPs designed for medical use are usually derived 
from materials deemed biologically safe, but it remains unclear how we 
define a ‘biologically safe’ material and in particular what investigations 
should be mandatory in the development of these materials. Unfortunately 
the behaviour of ENPs cannot be determined from their bulk properties; when 
relatively inert or safe materials in their bulk form are presented in the nano-
scale they may exert previously unseen harmful effects on cells and systems. 
If we are to maximise the potential of nanotechnologies in the field of 
medicine we must ensure that novel nanomaterials are rigorously tested 
before introduction to the clinic or any other arena where they can enter the 
body. 
 
The nanotechnology industry has exploded over the past twenty years the 
graph below demonstrates the number of publications relating to the word 
ENP on PubMed versus the number of publications mentioning toxicity and 
ENP. 




Figure 6-1 Breakdown of ENP Publications in PubMed (20.02.13) 
It’s obvious that the number of ENP being produced outstrips the rate at 
which their toxicity is being tested. It has been shown that inhaled ENPs from 
air pollution are associated with increases in cardiovascular morbidity and 
mortality with deaths due to ischemia, arrhythmia and heart failure [Brook et 
al., 2004]. These associations are strongest for fine particulate air pollutants, 
of which combustion-derived particulate in diesel exhaust is an important 
component. Whilst the mechanisms responsible for these associations are 
only partly understood, observational studies suggest that exposure to air 
pollution may worsen symptoms of angina, exacerbate exercise induced 
myocardial ischemia, and trigger acute myocardial infarction [Peters et al., 
2006]. Currently the thinking is that whilst a certain proportion of these ENPs 
will translocate across the lung blood barrier the majority will be taken up by 
phagocytic cells in the lung causing an inflammatory response which in turn 
can activate the endothelium and trigger an adverse cardiovascular event 
(Mills, Miller, Lucking, Beveridge, Flint, Boere, Fokkens, Boon, Sandstrom, 
Blomberg, Duffin, Donaldson, Hadoke, Cassee, & Newby 2011;Shaw, 
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Robertson, Miller, Duffin, Tabor, Donaldson, Newby, & Hadoke 2011). While 
most medical ENPs are designed to be introduced into the body 
intravenously by -passing the lungs and uptake by alveolar macrophages, 
question have been raised about the safety of introducing huge amounts of 
ENPs directly into the blood of people with underlying CV disease when 
CDNP in the lung exacerbates it (Donaldson & Seaton 2007).  We 
hypothesized that ENPs designed for clinical use could activate platelets and 
have prothrombotic effects when introduced into the blood. 
 
In Vitro Effects of Engineered Nanoparticles 6.2 
 
A series of in vivo tests were designed to determine how ENPs interacted 
with platelets and MDMØ. Platelets play a key role in thrombosis forming 
blood clots with fibrin at sites of injury around the body. Any abnormality in 
the coagulation of blood increases the risk of thrombosis and adverse cardiac 
events. Flow cytometry was used to measure the surface expression of 
platelet and leucocyte activation markers as well as platelet–leucocyte 
aggregates, a technique increasingly recognized as the gold standard 
measure of in vivo platelet activation, in patients with CV disease (Freedman 
& Loscalzo 2002). Aminated polystyrene and iron oxide ENPs activated 
platelets in vitro up-regulating platelet surface p-selectin, Pac-1 binding, 
platelet-monocyte aggregation and platelet-neutrophil aggregation.  Confocal 
microscopy was used to visualise the platelet-monocyte aggregates which 
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showed the aminated ENPs affiliation for the platelets suggesting the ENPs 
interact first with the platelets activating them which in turn mediates their 
binding to monocytes and neutrophils (Barnard, Krueger, Frelinger, III, 
Furman, & Michelson 2003;Freedman & Loscalzo 2002). The toxicity of 
aminated or cationic ENPs to platelets has been reported in the literature 
(Jones et al. 2012a;Jones, Campbell, Franks, Gibson, Thiagarajan, Vieira-
de-Abreu, Sukavaneshvar, Mohammad, Li, Ghandehari, Weyrich, Brooks, & 
Grainger 2012b). Here we demonstrated that cationic ENPs are more potent 
platelet activators when compared to anionic ENPs which we suggest is 
mediated by electrostatic interactions between the cationic platelet 
membranes and anionic amine groups on the ENP surface. These findings 
underline the need to fully characterise the adverse effects of amine 
terminated ENPs on platelets and their potential to cause toxicity.  
 
Platelet responsiveness shows marked individual variation with some people 
displaying high baseline platelet activity including response to agonists (Bray 
2007;Natarajan et al. 2008;Yee et al. 2006). This remains an important 
cardiovascular risk factor. Platelets incubated with various iron oxide ENPs 
showed significant increases in surface p-selectin and Pac-1 by flow 
cytometry to submaximal concentrations of known agonist TRAP-6 as well as 
an increase in calcium influx in response to thrombin. The hyper-reactive 
state induced was not ENP specific indicating a more global effect and the 
possibility that exposure of platelets to ENPs share common signalling 
pathways which make them more reactive to lower doses of agonists.  
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The use of iron oxide ENPs in clinical imaging has been well documented 
(Amirbekian et al. 2007b;Schmitz, Winterhalter, Schiffler, Gust, Wagner, 
Kresse, Coupland, Semmler, & Wolf 2002;Yilmaz, Rosch, Klingel, Kandolf, 
Helluy, Hiller, Jakob, & Sechtem 2011b) however most research on SPIONs 
has been dedicated to the synthesis, characterization, and surface properties 
of ENPs rather than  their biological impact.  
 
Whilst iron-oxide ENPs may not be particularly toxic this study demonstrated 
that depending on their surface functionalisation they could have pro-
inflammatory effects. Monocyte derived macrophage cells showed increase 
ICAM-1 expression as well as IL-8 protein in cell culture supernatants. Both 
of these have been implicated in the initiation and propagation of 
atherosclerotic disease mediating endothelial cell dysfunction and cell 
recruitment (Apostolakis et al. 2009;Galkina and Ley 2007). The unmodified 
and aminated ENPs had no pro-inflammatory effects on the MDMØ suggesting 
the carboxylation activated specific pathways on in the cell.  
The in vitro work carried out demonstrates that ENPs can behave very 
differently depending on their surface modifications and are not universally 
toxic or pro-inflammatory across all cell lines but act specifically depending 
on the functionalisation.  
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Ex-Vivo Effects of Engineered Nanoparticles 6.3 
 
Shear forces generated by flowing blood have significant impact on platelet 
adhesion and thrombus propagation. Such effects aren’t taken into account 
in many in vitro techniques, such as aggregometry. To factor this into our 
platelet studies we used a parallel flow chamber to carry out experiments 
under well controlled conditions of time, thrombogenic surface and flow rate. 
The objective of this study was to use an established model of ex-vivo 
thrombus formation to determine the pro-thrombotic potential of clinical 
ENPs. In a double blind randomised cross-over study healthy male 
volunteers attended the clinical research facility at the Edinburgh Royal 
Infirmary on two occasions where they underwent three runs of the Badimon 
chamber at each visit. For the volunteers the study involved no more than a 
blood donation as at no point were they in contact with the ENPs.  
 
During each run either a control (saline) or ENP formulation was added, 
extracorporeally, to the blood before it entered the chamber. The addition of 
the iron-oxide ENP Feraheme® to the chamber (300µg/mL) resulted in a 
significant increase in the chamber compared to the saline control. The lower 
dose (150µg/mL) caused an increase in thrombus though this did not reach 
significance. 
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In the in vitro studies it was demonstrated that exposure of platelets to ENP 
caused them to become hyper-reactive and more responsive to the agonists 
TRAP-6 and thrombin. Based on these observations it is likely that the 
platelets become sensitised or primed upon contact with the Feraheme® 
ENPs and the subsequent contact with the sub-endothelial matrix, combined 
with the high shear stress (1680 s-1) in the second and third chambers 
causes their arrest, adhesion, and thrombus formation. 
 
The latex beads used in the study were selected as they caused in vitro 
increases in platelet activation however when added to the Badimon 
chamber an overall decrease in thrombus was observed; as expected an 
increase in markers of platelet activation was observed. Due to the highly 
agonistic activity of these beads it could be that the platelets are simply 
activating and forming aggregates before they come in contact with the 
denuded aorta and passing straight through the chamber. 
 
The Badimon shows potential for use as an ex vivo model of thrombus 
formation with the extra-corporeal addition of  ENPs that show little in vitro 
platelet activation but may cause problems in vivo where other forces such 
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In Vivo Effects of Engineered Nanoparticles 6.4 
 
As a complimentary investigation to the ex vivo extracorporeal Feraheme® 
study patients with AAA were assessed for platelet activation and thrombus 
formation using the Badimon chamber both before and 1-hour after receiving 
Feraheme®.  At 1-hour post Feraheme® both platelet activation and 
thrombus area were significantly increased. From pharmacokinetic studies 
carried out the circulating concentration of Feraheme® 1-hour post infusion 
has been found to be 150µg/mL (Landry, Jacobs, Davis, Shenouda, & Bolton 
2005); this is the lower of the two doses used in the healthy volunteer, 
extracorporeal study (study 2). Whilst this dose did increase thrombus 
formation in study 2 it did not reach significance whereas when given in vivo 
to patients with underlying cardiovascular disease, significant increases in ex 
vivo thrombus were seen. This could be due to the underlying cardiovascular 
disease making the AAA patients inherently more susceptible to the effects of 
IV ENPs or the fact the ENPs had more time to interact with the blood (1-
hour) and activate circulating platelets. Whatever the mechanism it took half 
the dose of ENPs to cause similar increases in thrombus formation in AAA 
patients as opposed to healthy volunteers. 
 
Whether or not the platelet activation and thrombus formation seen in this 
study translate into clinical events or are merely a transient side-effect that 
clinicians should be aware of is unknown but what is clear is that medical 
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ENPs need more thorough safety profiling in susceptible populations in 
particular in patients with atherothrombotic disease. 
 
 
Future Directions 6.5 
 
These studies aimed to resolve a potentially important paradox in medical 
imaging and therapeutics: CDNPs are toxic to the cardiovascular system 
even at relatively low concentrations, yet in the quest to enhance 
cardiovascular imaging the cardiovascular community propose direct 
intravascular infusion of nanoparticles with similar structural properties at 
high concentrations in patients with unstable atherothrombotic disease. As 
this field develops more attention should be given to assay the potential 
toxicity of novel imaging agents and engineered nanoparticles. 
 
Given their importance in the outcome of cardiovascular disease a reliable 
method of assessing the effect of ENPs on platelet function could be a good 
predictor of their activity in vivo. Using readily available flowcytometric 
techniques it was shown that platelet activation could be detected both in 
vitro, ex vivo and in vivo and correlated well with thrombus formation in the 
Badimon chamber. Flowcytometry could be a useful technique in assessing 
the pro-thrombotic nature of ENPs before their introduction into the clinic; its 
fast, reliable and high throughput. It would rapidly determine which ENP 
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would directly activate platelets and could also be used for more subtle 
assessments of platelet biology such as response to agonists. The 96-well 
plate aggregometry could also be very useful as a fast, consistent measure 
of platelet activation; though not fully explored in this study there is a lot of 
scope for this technique to be employed in assessing platelet function testing 
up to 96 parameters in one experiment with very small amounts of blood.  
 
As well as screening ENP formulations before their introduction into the clinic 
we have a responsibility to monitor patients that have received those already 
in use more thoroughly and closely than we have been. From the ex-vivo 
chamber studies it was shown that 1-hour post infusion of Feraheme® 
patients had increased markers of platelet activation as well as increased 
thrombus area in the Badimon chamber. Whether or not this is clinically 
relevant might be difficult to determine with in vitro or ex-vivo methods, 
however it should be our responsibility to monitor any adverse events in 
these patients over the course of their life compared to patients that didn’t 
receive them. No routine post-marketing safety data is collected despite the 
novel nature of these drugs. The collection of this data would be relatively 
straightforward and provide a very meaningful method of monitoring the long-
term effects of introducing huge numbers of ENPs into patients with 
underlying inflammatory conditions such as atherothrombotic disease and go 
a long way to resolving the paradox. 
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APPENDIX I: Cytotoxicity Data Superparamagnetic 
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A range of cytotoxicity tests were carried out using the SPIO/USPIO from this 
study all with the conclusion that these particles can be considered low 
toxicity. The following data demonstrates the ENPs biocompatibility with a 
range of cell types, including platelets and MDMØ. Whilst not all the particles 
used were put through all the cytotoxicity tests I feel confident that 
USPIO/SPIO designed for medical purposes would demonstrate similar 
cytotoxicity profiles. 
 
Calcein-am staining was performed on platelets that had been incubated with 
ENPs for 30min and analysed by flow cytometry. Calcein-am is taken up by 
cells and cleaved by intracellular esterases to fluorescent calcein. This 
process can only be carried out by viable cells. 
Figure A 
 
Here it can be seen that the amine beads caused a 30% reduction in platelet 
viability after 30-mins whereas the Poly-COOH and SPIO had no such 
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effects. This is most likely due to the negatively charged platelet membranes 
being disrupted by the positively charged beads. 
 
Monocyte derived macrophage viability was determined using 
AnnexinV/Propidium iodide (PI) staining. MDMØ cells were incubated for up to 
72-hours with iron-oxide ENPs then stained for apoptosis (annexin V) and 
necrosis (PI). Any cells that didn’t stain were considered viable (Figure B) 
Figure B 
 
It can be seen that although there is a reduction in cell viability over the 72-
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Haemolysis was used to determine the toxicity of the Poly-Beads. 
Haemolysis was performed in washed red blood cells (RBC). RBC and ENPs 




Figure C clearly demonstrates that the positively charged amine beads were 
very haemolytic suggesting they readily disrupt cell membranes whereas the 
carboxylated beads do not. 
Cytotoxicity was not the focus of this study but is a necessary part of any 
work carried out with nanoparticles in vitro in vivo and ex vivo. While the 
SPION/USPIO and the Poly-COOH beads used in this study could be 
considered minimally toxic the aminated Poly-NH2 displayed considerable 
toxicity after just 30-mins in platelets and RBC. The effects the Poly-NH2 
beads have on cell membranes most likely accounts for the in vitro effects 
seen in platelets (chapter 3). Considering the toxicological profile of the 
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SPIO/USPIO demonstrated here I am confident they effects seen in vitro and 
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